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Summary 
Recent evidence suggests that 18-29% of eukaryotic genomes encode 
enzymes.1 However, only a limited proportion of these enzymes have thus far been 
characterized, and little is understood about the physiological roles, substrate 
specificity and downstream targets of the vast majority of these important proteins. 
While advances in sequencing and molecular biology have made it feasible to quickly 
amass a great wealth of genetic information, sparking the genomic revolution, similar 
capabilities are severely lacking in the relatively nascent proteomics arena. A key step 
towards the biological characterization of enzymes, as well as in their adoption as 
drug targets, is the development of global solutions that bridge the gap in 
understanding proteins and their interactions. This thesis examines and addresses 
these challenges by introducing a series of technologies that span various analytical 
modes, effectively expanding current capabilities in protein profiling by leveraging on 
throughput. These include microplate (Chapter 2 and 6) and microarray (Chapters 3-5 
& 7) platforms, for which I demonstrate with examples, novel methodologies to 
garner implicit functional understanding of enzymes through systematic in vitro and 
in silico experimentation. Cohesively, the methodologies are applied (but not limited) 
to investigations of metalloproteases – an important cluster of enzymes, whose 
expansive biological roles not only present pharmaceutical importance in combating 
diseases like cancer, arthritis and anthrax, but also provide functional insight into 
complex enzyme dynamics that orchestrate the remarkable enigma of life.  
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          Advances in genomics and proteomics have opened up new and exciting 
possibilities for the rapid functional assignment and global characterization of 
proteins. Novel tools and strategies have accelerated such large-scale studies by 
facilitating highly parallel analysis of huge repertoires of biomolecules. In 
addition to traditional approaches using microtitre plates, microarrays are 
becoming established as robust platforms for rapid screening, lead discovery and 
molecular characterization. The essential advantages of microarray and 
microplate technology are attributed to the massive throughput attainable, 
coupled with highly scalable platforms – driving discovery both as analytical and 
diagnostic tools. The scope of microarrays and microplates is expansive - 
virtually every biological component, from diverse small molecules and 
macromolecules (such as DNA and proteins) to entire living cells, has been 
harnessed on these platforms in attempts to systematically dissect the bewildering 
complexity of life. I will describe state of the art strategies in this chapter that 
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address challenges in proteomics with the aid of the aforementioned high-
throughput screening platforms. Of specific interest to the context of this thesis 
are applications that facilitate rapid enzyme profiling and characterization.  
1.2 The Nature of Enzymes – An Overview 
Enzymes are biocatalysts intimately involved with virtually every cellular 
process and metabolic exchange. These proteins are suitable candidates for the 
directed perturbation of cellular functions and thus serve as valuable therapeutic 
targets (enzymes represent nearly one-third of all current drug targets).2 Minor 
imbalances in enzymatic activities are known to cause debilitating diseases such as 
haemophilia and phenylketonurea, and even promote cancer and tumour metastasis.3-4 
Pathogenic organisms with orthologous enzyme systems present viable targets for 
treatment, and have fueled various antimicrobial therapies for example antibiotics, 
like penicillin (target: cell wall biosynthesis, transpeptidase) and fluoroquinolones 
(target: DNA gyrase), and antivirals, like acyclovir (target: herpes simplex virus 
polymerase), azidothymidine (target: HIV reverse transcriptase), saquinavir (target: 
HIV protease) and Relenza (target: influenza neuraminidase).5-6  
Amongst the different classes of enzymes, phosphatases and kinases are 
responsible for the phosphorylation/dephosphorylation of biomolecules, intricate 
control over which forms the basis of cell cycle regulation, signal transduction and 
cellular communication. Proteases participate in numerous physiological processes 
such as cell growth and differentiation, metabolism and cell death. By molding the 
proteome through the precise and irreversible processing of peptide/protein substrates, 
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proteases contribute an additional layer for signaling and regulation.7 At least 553 
genes have been annotated in the human genome to encode proteases or protease 
homologues.8 Various classes of proteases are distinguished by the mode of 
proteolysis and the relevant residues in the active site. These are divided into aspartate 
and metalloproteases both of which polarize a water molecule that acts as the 
nucleophile in the proteolysis, while cysteine and serine proteases initiate substrate 
cleavage through a nucleophilic amino acid side chain in the enzyme active site.9 
Consequently, much effort has been put towards a better understanding of the activity, 
biochemistry and cellular pathways controlled by enzymes, as well as in seeking 
novel pharmaceutical leads to modulate their activities. 
1.2.1 Metalloproteases as Therapeutic Targets 
1.2.1.1 Matrix Metalloproteases 
Matrix metalloproteases (MMPs) are a family of closely related zinc-
dependent proteases that play complex and diverse roles in vivo. Their collective 
involvement in tissue remodeling is vital for normal physiological development, and 
stringent control is placed over their activity at both transcriptional and post-
transcriptional levels.10 Minor perturbations of these enzymes consequently manifest 
in the deregulated catalytic degradation of the extracellular matrix - a defining feature 
in the pathophysiology of diseases such as cancer, cardiovascular diseases and 
arthritis.11-12 There has accordingly been intense interest in developing effective small 
molecule drugs against this class of enzymes.13 Recent studies have further identified 
MMPs (namely MMPs -1, -2 and -7) that directly accelerate tumorigenesis, 
implicating these enzymes as vital disease targets.4 In contrast, other closely related 
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members in the MMP family often confer valuable and protective effects in various 
human diseases. Stromal cells, for example, direct MMP activity beneficially towards 
tissue homeostasis, enhancing host resistance towards cancer and other 
abnormalities.5 Knocking-out certain MMPs (for example MMPs -3, -8 and -9) has 
also been directly linked to tumour proliferation in animal models of several cancers, 
underscoring the positive roles mediated by selective members of the MMP family.14 
This presents a delicate challenge in the development of effective therapies, which 
present good potency and selectivity against the target MMP(s) responsible for the 
disease phenotype, while leaving related members of the family, that play vital 
functions in vivo,  unaffected.   
1.2.2.1 Anthrax Lethal Factor (LF) 
 Anthrax is an infectious disease caused by a rod-shaped, gram positive, 
bacterium that infects humans through the skin, respiratory system or digestive tract. 
Though cutaneous anthrax is rarely lethal, inhalation anthrax is highly dangerous and 
fatal.15 Spores are phagocytosed by alveolar macrophages and carried to local lymph 
nodes where they germinate and multiply. The bacteria secrete three proteins that 
assemble in a binary mode to form the anthrax toxin. The protective antigen, first 
oligomerizes upon cleavage by furin, binds cellular receptors and finally transports 
lethal factor (LF) and the edema factor into cells where they exert downstream 
effects.16 The lethal factor cleaves members of the mitogen-activated protein kinase 
(MAPK) kinases near the N-termini that disrupts the ability of these enzymes to 
interact and phosphorylate downstream substrates. The edema factor is a calmodulin 
activated adenylate cyclase that is approximately 1000-fold more active that 
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endogenous counterparts, causing a steep rise in cAMP levels.17 The combined effect 
of the toxin is cell lysis and tissue edema. By evading the innate immune system 
through killing macrophages, uncontrolled bacteremia eventually leads to systemic 
shock and death.18  
Various levels of therapeutic intervention have been studied as potential 
solutions against this bioterror threat. Countermeasures include vaccination, antibody-
based therapies, antibiotics as well as antitoxins. Though each strategy in part have 
not been effective in disease management, combinations of the abovenamed 
approaches have potential for increased efficacy and promote patient survival. 
Antibiotics therapies, for example, ciprofloxacin that inhibit the anthrax  
topoisomerase, may be used in tandem with antitoxins that prevent entry or inhibit 
protease activity to minimize the toxic load and enhance immune clearance.19 This 
necessitates a clearer understanding of the protein components of the toxin and the 
discovery of improved ways to impede their deadly mission.       
1.3 Microplate Technology – The Advent of HTS 
  Major pharmaceutical companies launch 20-35 screening campaigns annually, 
each taking a target of interest with screens ranging from 100,000 to 500,000 
compounds.20 This contributes a massive 2-18 million screening results, which are 
evaluated for hits that are channeled into the drug discovery pipeline. The screening 
throughput is set to increase in the years to come, not only because of developments 
within the microplate screening arena, but also from maturation of other high-content 
platforms like microarrays (introduced in the next section), mass spectrometry, bead-
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based libraries and encoding strategies. Positive contributions to drug discovery are 
also being coming from advances in bioinformatics, in silico screening and data 
mining approaches.  
  The concept behind high-throughput screening is, in principle, straight-
forward.21 Advances in combinatorial chemistry and synthesis have since the early 
90s made it possible since to generate huge libraries with expansive chemical 
diversity. These compounds are fed into parallel assays with a protein of interest and 
evaluated for either binding affinity or potency in inhibiting (or activating) specific 
enzyme reactions. The handful of compounds that succeed in these assays are termed 
“hits” that progress into further evaluation and development steps of the pipeline, that 
filter molecules based on druggability, toxicity and specificity to the target of interest. 
After further optimization, the surviving hits (now termed “leads”) and undergo 
animal-testing, before entering clinical trials. One of the most notable examples from 
a successful screening of a combinatorial compound library was the discovery of 
Gleevec, an BCR-ABL tyrosine kinase inhibitor implicated in chronic myeloid 
leukemia, a blockbuster drug under Novartis.22  
1.3.1. Assay Formats 
  The workhorse of the high-throughput screening has been the microtiter plate 
(microplate) where 96/ 384 assays may be conducted within a standard two 
dimensional plate. “Ultraminiaturized” plates (≥1536 wells) are being used for ultra-
high throughput screening where 10,000-100,000 assays may be conducted over a 24h 
period.20 Precision instruments have enabled assembly of reactions ranging from 
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hundreds of microlitres (into typical 96/384 well plates), down to the present 5-10 μl 
for 1536 well plates and 1-2.2 μl with 3456 well plates. New developments could see 
the development of a 20,000 well plate that enables 25 nl reaction volumes, bringing 
throughput of high-end systems to 1.5 million compounds that may be screened a 
week. These would require the development of more precise instruments that can 
dispense sub-nanolitre quantities of reagents, and may become available in the near 
future.20    
  Various instruments have also enabled a variety of parameters to be analyzed 
in high-throughput using microplates. These include readers that perform fluorescent, 
chromogenic or luminescence based measurements, in a convenient, safe and 
sensitive format. Apart from these established technologies, fluorescence resonance 
energy transfer, bioluminescence energy transfer and enzyme complementation assays 
are being applied to molecular discovery on microplates.23 Cell-based assays in 
microplate provide a rapid avenue to screening biological activity of compounds in an 
in vivo setting. Applications include studies of molecules that have an effect on 
transcription using appropriate constructs with reporter proteins, like green 
fluorescent protein or β-galactosidase.24 Fluorescent sensors are also making it 
possible to monitor cell signalling processes, for example, detecting calcium levels 
using dyes such as FLUO-3 or protein reporters like aequorin upon chemical 
stimulation.25    
1.3.2 Recent Advances and Developments 
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  In the quest to investigate the substrate specificities amongst groups of closely 
related enzymes, Craik et al. have synthesized a positional-scanning library of 
coumarin based peptides. Liberation of the coumarin fluorphore upon proteolysis 
contributes to enhanced fluorescence, allowing readouts that correspond 
quantitatively to the enzyme preference of the respective peptide sequence. A library 
was generated to explore the P1-P4 selectivities using permutations of the 20 standard 
amino acids, providing a set of 80 peptide libraries that were screened against 6 
cathepsins and other cysteine proteases.25 The profiles highlight discriminating 
signatures against each protease that could fuel the development of peptide based 
therapies against the enzymes tested. The group has also profiled seven tissue 
kallikreins, a class of trypsin-like serine proteases, using the same strategy.26
  While most HTS experiments are performed at a single concentration, a much 
better fidelity of data was obtained by performing over a range of inhibitor 
concentrations. Austin et al. have shown that the incidence of false positive and 
negative in HTS can be reduced with dose-response screens.27 Pyruvate kinase was 
screened against a library of over 60,000 compounds, to reveal a subset of 4,324 
inhibitors and 1,156 activators. The quantitative approach to screening provided a 
more robust dataset for the establishment of more accurate structure-activity 
assessments that may be obtained from such large-scale screens.      
  Another interesting development applied whole organism assays in high-
throughput. Studies with zebrafish embryos have also been performed in microplate in 
attempts to correlate aberrant phenotypes with causative molecular species from 
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within a combinatorial library, akin to a gene knockout strategy to assign protein 
function. This forward chemical genetic approach led to the discovery of a triazine 
compound involved in the inhibition of ribosomal proteins responsible for early 
brain/eye development.28       
1.4 Microarray Technology – Advances and Developments 
  Over the last decade, microarray screening has transformed the life science 
research landscape. Novel applications ranging from expression profiling29 and 
mapping interaction networks to molecular fingerprinting and ligand discovery,30 
have significantly impacted both basic and applied spheres of research. Creative 
ideas by biologists, chemists and engineers alike are propelling this 
interdisciplinary technology to interesting new levels. The numerous successful 
examples have inspired a growing following of scientists to take on high-
throughput, discovery-driven research, drawing impetus towards accelerated 
information assimilation and knowledge growth.  
  Microarray technology was first introduced as miniaturized DNA 
assemblies on chips. However it did not take long before further pioneering efforts 
made it possible to sequester small molecules31 and subsequently proteins32 in 
addressable grids for rapid analysis. Now it has also become feasible to examine a 
host of other biomolecules, including membrane proteins,33 carbohydrates34 and 
peptides,35 as well as complex structures like tissues36 and even live cells on 
arrays,37 providing a tremendous opportunity for screening and large-scale 
analysis. It is remarkable that so many diverse applications have stemed from a 
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single technology platform. With microarrays, this is attributed to significant 
advantages rooted in miniaturization, parallelization and automation. Breaking 
away from microtiter-based (or well-based) assays, microarrays offer a flat 
reaction surface that ameliorates the washing and incubation steps, while 
providing a significantly  higher sample density. This design concept makes it 
convenient to undertake thousands of assays quickly and cheaply by effectively 
reducing the amount of often precious reagents required to perform highly 
informative experiments. The commercial availability of complementary research 
infrastructure is equally important in catalyzing interest and outreach of this 
technology platform, making it readily accessible to any researcher interested and 
willing.38  
  Every molecular class displayed on arrays presents  distinctive challenges 
while offering unique opportunities.39 Small molecules and protein microarrays 
have witnessed tremendous growth in recent years with significant technical and 
conceptual improvements made towards library creation and immobilization 
formats. These developments, together with novel advances herein described, have 
set the foundation for these platforms to eventually take on more routine 
applications in discovery and diagnostics.40  
1.4.1 Protein Microarray 
  The first report of using protein arrays for protein-protein interaction, 
ligand binding and biochemical investigations was by MacBeath and Schreiber in 
2000.32 Though the variety of proteins tested was small, it dispelled initial 
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scepticism of proteins losing their activities when covalently immobilized on glass 
surfaces - a critical consideration when studying proteins on arrays (in this case 
aldehyde-derivatized slides were used). Proteins are complex molecules, thus 
comprehensive global analysis of proteins in a parallel format is no trivial task. It 
was thus a significant developmental milestone when Snyder’s group reported the 
yeast proteome array in 2001,41 where 5800 yeast open reading frames were 
expressed and presented on a single glass slide for large-scale proteomic analysis. 
The protein collection was individually purified and tethered via a hexahistidine 
motif onto nickel-coated slides before being screened simultaneously for 
interactions with calmodulin. This resulting microarray has been commercialized 
(Yeast ProtoArrayTM, Protometrix, Invitrogen) and since been used for a variety of 
applications.42 Since these seminal works, protein microarrays have generally seen 
major developments in two major aspects, in terms of immobilization methods for 
anchoring huge repertoires of proteins and expanding areas of applications using 
novel strategies. These will be discussed in the following sections.    
1.4.1.1 Array Fabrication Strategies 
  Immobilizing proteins stably onto chips is the first and most fundamental 
step in any successful protein microarray venture. Factors such as molecular 
orientation, immobilization chemistry and protein stability are key considerations 
that govern how the proteins are presented for parallel analysis and screening.43 
Some groups have sought the use of “capture” agents like aptamers or antibodies 
to assemble proteins as microarrays. Though the involvement of an intermediary 
molecule avoids direct covalent immobilization, this approach introduces concerns 
 11
of cross-reactivity of the intermediary scaffold itself and binding stability, 
problems that are avoided with direct covalent tethering. The latter strategy could, 
however, be more vulnerable to loss of protein function upon immobilization, a 
phenomenon peculiarly difficult to circumvent on any support base, but is 
generally minimized in microarrays by selecting suitable immobilization 
strategies, appropriate buffering conditions for spotting and low temperature 
storage of printed slides.  
  Recent developments have expanded the microarray “toolbox”, providing a 
plethora of options depending on the downstream screening requirements. This has 
included a variety of chemistry introduced to immobilize proteins (some of which 
may have equal applicability to small molecules, including  peptides), as well as 
strategies for self-assembly and in situ microarray creation. Immobilization 
chemistry takes on two typical formats, either regioselective immobilization which 
results in non-uniformly oriented proteins (for example using aldehyde surfaces 
which may bind to any available amine group in a protein), or site-specific 
immobilization which orientates all proteins uniformly (for example by His-tag 
immobilization). 
  Our group recently developed a versatile purification and tagging approach 
of proteins using inteins (ie. spliceable protein motifs).44 Proteins were first 
expressed with a C-terminal intein and chitin-binding domain for affinity capture 
on chitin columns. The proteins were then treated with a cysteine-biotin conjugate, 
which triggered the intein cleavage to release the protein from support and 
simultaneoulsy tagged it with biotin. This intein-mediated biotinylation approach 
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provides a feasible strategy for purifying large numbers of proteins in a scalable 
format for high-throughput immobilization onto avidin-coated glass surfaces.44 
The stability of the avidin-biotin linkage is an additional feature that represents a 
highly stable and extremely strong tether for array creation. We further 
demonstrated our intein mediated strategy could be readily applied to biotinylate 
proteins both in live cells (bacteria and mammalian cells) as well as in established 
cell-free protein expression methods.45 This demonstrates the versatility of the 
strategy in preparing proteins for immobilization on protein microarrays. 
  An alternative strategy has since been developed that uses inteins in the 
introduction of N-terminal cysteine containing proteins that can chemoselectively 
react (by native chemical ligation) with thioester groups on derivatized slides 
(Figure 1.1A).46 The same concept has been applied in reverse, by introducing the 
thioesters on the C-terminus in a protein (also by intein cleavage) for reaction with 
cysteine-derivatized surfaces, thereby anchoring proteins through their carboxy 
terminus (Figure 1.1A).47 Compared to the previous strategy,44 both these methods 
mediate covalent attachment of proteins onto treated slide surfaces. These 
strategies also share the advantage of employing small tags that minimally perturb 
the overall protein architecture, presenting them close to their native state for 
interaction and binding assessments. Tirell and colleagues have developed a 
capture strategy by exploiting heterodimeric leucine zipper pairs.48 Proteins to be 
immobilized were fused with the ZR domain as an affinity tag for capture on 
slides coated with the complementary ZE capture domain (Figure 1.1B). The 
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strategy was succesfully demonstrated using glutathione-S-transferase (GST) and 
green fluorescent protein.  
    Lahiri et al. introduced a method to immobilize membrane proteins on 
arrays,49 thereby expanding the scope of protein microarrays beyond soluble 
proteins. Membrane monolayers were generated using vesicular solutions of egg-
yolk phosphatidyl choline (PC) with dihexadecanoylphosphatidylethanolamine or 
4:1 mixtures of dipalmitoyl PC/dimyristyl PC on  γ-aminopropylsilane (GAPS)-
coated slides. Three G-protein coupled receptors (GPCRs) were spotted on these 
membrane arrays which were found to localize stably on this lipid support and 
were accordingly presented for ligand binding assessments. The group recently 
developed an alternative porous glass substrates (also coated with GAPS) as a 
more robust surface for probing functional interactions of GPCRs.49   
  Further approaches to generate protein arrays have emerged from 
extensions of DNA-based approaches. For example, Weng et al. tethered in vitro 
translated proteins with their coding mRNAs, and subjected these assemblies on 
slides printed with complementary nucleotide sequences.50 This strategy was 
shown to localize the protein conjugates to predefined “addresses” by simple 
hybridization. It was also demonstrated that the relative amount of immobilized 
proteins could be directly controlled by varying the concentration of the capture 
oligonucleotides spotted. This strategy, termed PROfusion™ technology, adopts 
traditional DNA microarray stategies for the provision of protein microarrays by 
self-assembly. Choi et al. devised an alternative strategy also using DNA surfaces 
by exploiting the GAL4 DNA binding domain to generate fusion proteins for 
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immobilization onto slides coated with the target dsDNA sequence (that binds 
with the GAL4 domain selectively, with a low dissociation constant in the 
nanomolar range).51   
  Ramachandran et al. have since taken the strategy a step further by 
immobilizing a variety of plasmids (cross-linked using ultraviolet light to 
psoralen-biotin) that code for target proteins together with a C-terminal GST 
epitope.52 During the printing process, anti-GST antibodies were co-immobilized 
together with avidin and the biotinylated plasmids onto predefined locations on the 
array. Proteins were expressed by subjecting the array surface to in vitro 
transcription and translation, allowing each protein to be immobilized in situ 
through the GST tag (Figure 1.1C). Cross reactivity between spots was shown to 
be negligible by using suitable spotting densities as well as other optimized 
conditions. The strategy, termed nucleic acid programmable protein array 
(NAPPA) enables long-term storage of the stable DNA microarrays, which can be 
readily converted, when required, into active protein microarrays.  
 15
























Y In vitroTranscription and 
Translation  
Figure 1.1 Various strategies developed for fabricating protein microarrays (A) 
Covalent attachment using native chemical ligation.45,46 (B) Leucine zipper domain 
hetrodimerization.47 (C) Nucleic acid programmable protein array.52  
1.4.1.2 Applications 
  Protein microarrays are highly informative tools that have been used for 
high-throughput interaction studies with various biomolecules including proteins, 
DNA and small molecules as well as in biochemical investigations of protein 
activity for functional annotation and characterization. 
 
 16
1.4.1.2.1 Mapping protein interactions 
  There is much potential in screening whole proteome microarrays for a 
variety of different purposes. It provides a unique window into the the ensemble of 
proteins present in an organism for parallel analysis; offering huge opportunities in 
screening potential drug interactions as well in detecting post-translational 
modifications that regulate protein behaviour. The yeast proteome array has 
already been succesfully shown to probe for novel interacting partners of 
calmodulin as well as in the discovery of phospholipid binding proteins.12 It has 
also been employed to study the specificity of eleven commercial polyclonal and 
monoclonal antibodies against yeast proteins, as well as three antibodies 
commonly used against specific epitopes (haemagglutinin, FLAG and myc) 
allowing thorough examination for cross-reactivities.53 As expected, the 
monoclonal antibodies exhibited higher specificity than their polyclonal 
counterparts; whilst among the polyclonal antibodies, those targeting peptide 
motifs had the highest relative specificity.  
  The yeast proteome array was also used to identify potential targets of a 
small molecule that suppresses the growth inhibition of rapamycin.54 The 
biotinylated molecule was screened on the yeast proteome array and revealed two 
potential target proteins, Tep1p and Nir1p, that associate with 
phosphatidylinositides, providing insight to how the pathway might be regulated. 
This study clearly demonstrates the utility of screening small molecules against 
protein arrays, especially in revealing the mechanism of action of drug candidates.  
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  In an attempt to probe gene regulation, Hall et al. described a hybrid 
approach using both protein microarray and the chromatin immunoprecipitation 
(ChIP-chip) method to map novel protein-DNA interactions.55 Briefly, 
fluorescently labelled genomic DNA was screened on the yeast proteome array to 
shortlist over 200 putative DNA-binding proteins. Eight of these proteins, that had 
not been previously known to bind DNA, were selected for further investigation 
using the ChIP-chip strategy. By subjecting the DNA immunoprecipitated from 
the shortlisted proteins to conventional DNA microarray analysis on an intergenic 
chip, the DNA sequences targeted by these proteins were conveniently unravelled. 
To further expand the prospect in proteomic profiling on arrays, a human 
proteome array containing 3000 proteins has recently been made available 
(Invitrogen), opening up even greater avenues for research.  
  DNA interactions with immobilized proteins have also been used to map 
p53 binding interactions with the GADD45 promoter.56 The simultaneous 
presentation of an array of p53 variants enabled rapid functional characterization 
of the p53 protein in relation to its polymorphic forms. The array was also 
screened for MDM2 interactions as well as for p53 phosphorylation by casein 
kinase II.        
  Protein arrays have also been used in more specialized applications. 49 
coiled-coil strands of human leucine zipper transcription factors were screened on 
microarray for interactions.57 Letarte et al. have used protein microarrays for 
epitope mapping of human leukocyte membrane protein (CD200).58 A similar 
strategy was also employed by Poetz et al. in the detailed characterization of 
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binding profiles of recombinant Fab fragments.59 Protein microarrays have also 
been used to identify 14-3-3 kinase interactions with tuberin, proteins involved in 
phosphotidylinositol 3’-kinase signalling.60 A microarray was prepared with 
candidate protein domains and motifs, including 14-3-3 proteins, and screened 
against phosphorylated and non-phosphorylated tuberin peptides. Estrogen 
receptors have also been immobilized on aldehyde surfaces for ligand binding 
assays.61  
1.4.1.2.2 Global protein profiling 
  Our group has developed a strategy that enables the rapid  analysis and 
discovery of different classes proteins in a microarray.62 By taking advantage of 
fluorescently labelled, mechanism-based suicide inhibitors (targeting serine 
hydrolases, phosphatases and cysteine proteases), we were able to selectively 
identify and label proteins immobilized on the microarray in an activity-dependent 
manner. The strategy was tested with twelve representative enzymes and the 
probes were shown to exclusively label the targeted classes of enzymes 
(immmobilized regioselectively on epoxy treated slides). Not only did this 
demonstrate that enzymatic activity is preserved when proteins are immobilized on 
the surface, but also furnished unique opportunities in enzyme characterization 
and functional annotation in a high-throughput fashion using microarray. We have 
recently extended this approach to the fingerprinting of protein activities on 
microarrays using a novel repertoire of activity-based probes that are able to 
evaluate protease specificity irrespective of class.63  
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   Building on this approach, Eppinger et al. have developed a strategy for 
kinetic determination of enzyme activity on microarray.64 Papain, a cysteine 
protease, was immobilized on N-hydroxysuccinimide (NHS)-activated hydrogel 
slides and reacted under a variety of concentrations and for different periods of 
time with a fluorescently labeled suicide inhibitor against the enzyme. The 
fluorescent data obtained was normalized and analyzed to obtain kinetic constants 
of the enzymatic reaction. The strategy was further explored to determine the 
inhibition constants of known inhibitors of papain, by subjecting titrated mixtures 
of these inhibitors with the immobilized enzyme. The same group has further 
employed this microarray strategy to profiling a group of six cathepsins, an 
important class of cysteine proteases, against a seven known inhibitors, obtaning 
inhibition constants which were in good agreement with those from traditional 
approaches.65  
  The ability to perform such activity-based profiling studies of enzymes in 
whole proteomes has also been recently demonstrated. Sieber et al. have used an 
antibody array platform to capture enzymes of interest from complex proteomes 
that were pretreated with fluorescently tagged activity-based probes, forging 
enzyme profiling in a complex cellular mileu with the advantage of high-
throughput deconvolution (by capture) and analysis on microarrays.66 Both serine 
proteases and metalloproteases were screened using this approach. However, even 
as the range of activity-based probes is being expanded greatly to cater to almost 
every enzyme class (potentially enabling multiple enzyme classes to be profiled 
simultaneously), the bottleneck in applying this strategy lies in the availability of 
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high-quality antibodies for studying every protein of interest. Apart from 
applications in enzyme profiling, Stephanopoulos and colleagues have developed 
an alternative application of enzyme arrays for pathway optimization.67 By 
immobilizing enzyme mixtures in different proportions in spots on the array, the 
authors showed that it was possible to optimize various biosynthetic pathways in a 
high-throughput manner, including the five-step pathway for trehalose 
biosynthesis. This strategy provides clear opportunities for industrial biosynthesis 
applications. 
1.4.1.3 Recent developments 
  New directions and creative ideas are fuelling exciting methodologies in 
deploying and using protein microarrays. Some of these interesting concepts will 
be discussed in this section, offering a sense of things to come as well as in 
describing frontier technologies that will benefit from further development.  
  Several groups are building capabilities that would soon allow for even 
greater miniaturization in protein microarrays. Gu et al. created “nano-wells” 
using conductive atomic force microscope (AFM) lithography, of diameters and 
depths of 91±6 nm and 1.31±0.12 nm respectively, within oligo (ethylene glycol) 
monolayers assembled on silicon surfaces.68 Avidin was succesfully immobilized 
in these wells and detected using fluorescently-labeled biotin. His-tagged ubiquitin 
and thioredoxin have also been immobilized in nanowells using dip-pen 
nonolithography on nickel surfaces, without the requirement of an applied electric 
field.69  
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  Surface plasmon resonance (SPR)-based approaches offer label-free 
measurement of protein interactions, providing a useful complement to 
fluorescence-based methods which currently dominate in microarray detection and 
analysis.70 Usui-Aoki et al. were able to perform 400 real-time antibody 
interaction measurements simultaneously on a specialized protein chip and 
detector.71 Ha et al. have also used spectral SPR sensors to analyze multiple 
proteins on arrays.72 An alternative strategy has utilized self-assembled 
monolayers on a gold surface together with MALDI-TOF MS for label-free 
detection of protein interactions on biochips.73  
  In a creative synergy of electrospray ionization coupled with array creation, 
Ouyang et al. have developed a method to deposit proteins separated by mass 
spectrometry onto microarrays.74 The technique, termed ion-soft landing, was used 
to separate and deposit four proteins, namely cytochrome c, lysozyme, insulin and 
apomyoglobin while retaining their biological activities on gold surfaces. This 
method is significant in that it is able to selectively isolate proteins in a mixture 
and presents them for parallel analysis on microarrays. The strategy has also been 
applied to arraying small molecules.75  
1.4.2 Small Molecule Microarray  
  Small chemical molecules provide efficacious handles in the selective 
perturbation of protein functions. This property makes small molecules viable drug 
candidates, and rapid evaluation of repertoires of small molecules for biological 
activity is thus the fundamental first step in drug discovery. Development of 
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robust screening tools, including small molecule microarray (SMM), is 
foundational for the pursuit of efficacious drug candidates and biologically 
relevant compounds. Discovery of molecules that modulate protein functions 
provides unique insights into various cellular mechanisms, allowing biological 
pathways to be better targeted and controlled. Modern synthetic approaches 
complement the vast diversity and complexity of natural products by contributing 
libraries of compounds for parallel analysis on microarrays. The massive number 
of compounds now available through large-scale solid phase synthesis and 
combinatorial chemistry is making it necessary to develop even more robust 
screening capabilities.  
  SMM was first introduced by Schreiber and colleagues in 1999.32 The same 
group has pioneered the diversity-oriented synthesis (DOS) approaches; capturing 
even larger realms of chemical space for simultaneous screening on SMM.76 The 
one-bead-one-compound (OBOC) combinatorial approach has further catalyzed 
library generation capabilities and has also been succesfully applied to SMM.77  
1.4.2.1 Library design for array-based screening 
  It would be ideal to develop immobilization strategies that could 
immobilize any molecule without concern over binding compatibility, orientation 
and surface properties. However, until such a global solution materializes, 
functional group selection remains a key consideration in library design and 
synthesis. Specifically, the small molecules should possess specific affinity 
handles that react predictably and chemoselectively with the corresponding 
functional groups on the substrate surface. As progress is made in synthetic 
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strategies in lieu with different types of sophisticated immobilization chemistry, 
we may one day be able to immobilize any compound conveniently in an array 
format for high-throughput screeing. Already a greater attention to this problem  
has given rise to major improvements, spearheading progress both in expanding 
the varieties of chemistry available for molecule immobilization as well as 
generating technologies to sequester both chemical and natural product libraries on 
microarrays.   
  Several strategies for developing chemical libraries compatible with SMM 
immobilization have been developed.  Germeroth et al. preppared SMM in which 
the small molecule library was synthesized directly on the substrate itself.78 1,3,5-
triazines were directly synthesized on cellulose or polypropylene membranes by 
SPOT synthesis.79 A similar strategy was also reported Blackwell and colleagues 
in the use of the Ugi four-component reaction to construct small molecule arrays 
on cellulose membranes.80 In contrast, the majority of chemical libraries used in 
SMM’s are synthesized on other platforms before immobilization on the 
microarray. A clear example of this route is the DOS libraries developed and 
exploited by Schreiber et al. for array-based applications.81-84 One study reported a 
library comprised 3,780 structurally unbiased 1,3-dioxane small molecules 
synthesized by split-pool synthesis using a “one bead-one stock solution” 
approach.81 This was used in the dissection of a signalling pathway mediated by 
glucose by identifying ligands of the protein Ure2p.82 Another development saw 
the synthesis of 6336 phenol-containing fused bicycles and tetracycles from a six-
step stereoselective synthesis.77 This strategy afforded products with between two 
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to four rings and up to 6 stereocenters. These compounds were immobilized on 
diazobenzilidene-functionalized glass surfaces that captured phenol and other 
groups of comparable acidity. The microarrays were screened against Cy-5 
labelled calmodulin and to afford 16 putative hits, revealing the strongest ligand 
that bound with a Kd of 0.12 ± 0.03 μM. 
  Hydroxyl-functionalized molecules have also been immobilized on 
chlorinated glass slides.83 Three libraries were combined to provide 12,396 
compounds immobilized on a single array. One class of the compounds was 
generated through the 1,3-dioxane synthetic pathway, whilst the two other libraries 
were made from biaryl scaffolds using DOS.84 The arrays were screened against 
Hap3p (a component of a yeast transcription factor complex) and visualized using 
Cy-5 labeled anti-GST antibody. Of the two hits obtained from the array screens, 
only one was found to truly bind to Hap3p (with a dissociation constant of 5.03 
μM), whilst the other was discovered to bind GST. This ligand was further found 
to inhibit Hap3p in vivo. Further modifications of this molecule provided a more 
potent ligand against Hap3p with a Kd of 0.33 μM. 
  We have developed a SMM using 1,3,5 triazines as this scaffold has 
demonstrated desirable bioactivity.85 Unlike typical one bead-one stock DOS-
based approaches earlier described, the parallel synthetic strategy adopted enabled 
the identity of each small molecule to be known a priori, facilitating immediate 
post-screening identification of hits. The library synthesis incorporated diverse 
linkers, taking into account of the linker effect in overall molecular potency. This 
further enabled the direct use of these molecules in solution-based assays, without 
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any modification or linker removal.86 After immobilization through an amine-
containing linker onto N-hydroxysuccinimide derivatized slides, the molecules 
were screened with human IgG for the discovery of safe and cost-effective small 
molecule alternatives of Protein A and Protein G for industrial antibody 
purification and production. The best hits obtained were subjected to SPR 
analysis, affording the tightest binder with a Kd of 2.02 μM. 
  Schultz and coworkers have developed a unique approach in generating 
libraries for SMM through the use of peptide nucleic acids (PNAs).87 The PNA 
moeity was used to encode the ligand identity and at the same time bears the 
unique advantage of its synthetic flexibility, resistance to degradation within a 
biological milieu, and most importantly its ability to hybridize with a 
complementary strand of DNA. The PNA-conjugated ligand libraries were 
incubated with the target while DNA-based microarray was used in the rapid 
deconvolution of the positive hits. The PNA libraries were synthesized using 
established procedures.88  
1.4.2.2 Array fabrication strategies 
  Several methods have been described for the development of small 
molecule microarrays, including covalent immobilization, photoactivatable cross-
linking and in situ synthesis. As with protein microarrays, immobilization is 
critical in SMM preparation as it determines the way in which the molecules are 
oriented for interaction with targets. Depending on the requirements, a 
homogenous orientation may be preferrable, as in enzyme characterization. 
However in the case of epitope binding, it may be desirable to randomly 
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immobilize the small molecules so as to expose every available facet for 
interaction.   
1.4.2.2.1 Covalent immobilization  
There have already been a variety of established chemistry for the covalent 
attachment of molecules onto arrays. Methods using aldehyde, NHS and epoxy 
surfaces to capture amines,  native chemical ligation as well as other more 
specialized binding chemistry have already been mentioned in earlier sections so 
will not be repeated herein. In this section we focus on more recently introduced 
strategies for the covalent capture of small molecules onto microarrays.  
  Waldmann et al. have established a highly chemoselective method for 
attachment of compounds on array.89 The strategy exploits the Staudinger ligation 
that couples azide-functionalized molecules with a phosphane-derivatized glass 
substrate (Figure 1.2A). This method has the desirable advanatage in that it 
utilizes a pair of reactive functional groups that are biologically inert. This 
strategy is compatible with water and oxygen and is also suitable in a wide variety 
of solid-phase synthetic strategies. 
  Increasing the density of molecules that may be immobilized within the 
same spotting surface could effectively improve the sensitivity of array-based 
applications.  It was with this aim that Puskas and co-workers used dendrimer 
linkers to greatly increase immobilization efficiency with reduced backgrounds. A 
variety of different surfaces were developed for the covalent immobilization of  
small molecules (as well as nucleic acids and proteins) through acrylic and epoxy 
reactive surfaces.90  
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1.4.2.2.2 Photoactivation strategies 
  Mrksich et al. assembled alkanethiolate monolayers (SAM) consisting of 
nitroveratryloxycarbonyl (NVOC)-protected hydroquinone groups on gold-coated 
substrates.91 By site-directed UV irradiation using a photomask, the NVOC group 
was selectively liberated to generate hydroquinone, which underwent spontaneous 
chemical or electrochemical oxidation to give benzoquinone. This reaction renders 
the surface reactive to cyclopentadiene-tagged ligands (Figure 1.2B). The 
technique was found to be amenable to techniques such as AFM and near field 
scanning optical microscopy (NSOM), making further miniaturization of the 
format possible. 
  Kanoh and colleagues have used a photoinduced cross-linking reaction to 
anchor small molecules on microarray using a strategy that allows multiple facets 
of the molecule to be exposed for interaction.92 A photoactivatable diazirin linker 
was coated on the slide surface. Following UV irradiation, the resulting reactive 
species generated on the surface reactes with proximate small molecules in a 
functional group-independent manner, leading to small molecule immobilization. 
This thus eliminates the need for specific functional groups amongst library 
members and is therefore well suited for immobilizing naturally derived 
repertoires of compounds.  
1.4.2.2.3 In situ synthesis 
  There have been recent developments that enable the direct  synthesis of 
small molecule microarrays in situ. Belshaw et al. have introduced orthogonal 
safety-catch protecting groups based on trimethoxyphenacyl group.93 These 
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groups were used for the maskless light-directed synthesis of a 2 x 2 small 
molecule microarray that may be broadly extended for the synthesis of even larger 
libraries (Figure 1.2C). A similar strategy was developed using peptoids 
(oligomers of N-substituted glycines). Kodadek and colleagues immobilized 
MeNPOC-protected glycolic acid onto chemically modified slides through an ester 
linkage. Irradiation with UV light-activated specific regions of the slide exposed 
hydroxyl groups which were then activated with tosyl chloride followed by 
displacement with a primary amine.94 The stepwise method of microarray 
synthesis in this manner facilitates the rapid creation of large molecular diversities 
with a only few synthetic steps.95 It is also possible to automate the entire 
procedure, reducing the time taken for array creation. The spot density may also 
be further enhanced, expanding greatly the number of compounds that may be 
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Figure 1.2 Various strategies developed for fabricating SMM. (A) Covalent 
immobilization using Staudinger ligation.89 (B) Photoactivation strategy followed by 
capture.91 (C) Sequential molecular assembly in situ.93  
1.4.2.3 Applications 
  Small molecule microarrays are well established tools in discovering 
ligands for virtually any target. In addition to the various examples earlier 
described,81-84 Schreiber et al. synthesized 18,000 enantioenriched and skeletally 
diverse 1,3-dioxanes for evaluation on array.96 This represents the first report of 
stereochemically diverse sets of small molecules to be immobilized and screened 
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on SMM. Each member of the library was chemically encoded. Subsets of this 
library were immobilized by diisocyanate capture and screened against 
calmodulin. Patterned incorporation of heptamethyleneimine elements in the 
molecular scaffold was found to bear importance in binding to calmodulin. Several 
ligands with low micromolar dissociation constants against the protein were 
subsequently identified. A large assortment of small molecules immobilized on 
microarray also offers a new way of analyzing proteins. Mihara and colleagues 
used an array of fluorescent labeled looped peptides to obtain “protein 
fingerprints” against a diverse set of proteins.97 Using a large library of peptoids, 
Kodadek et al. obtained unique binding “fingerprints” against three proteins, 
namely GST, maltose-binding protein and ubiquitin.98 Specifically, 7680 
octameric peptoids were synthesized in situ and presented on a maleimide-
functionalized  glass slide. Upon screening with the target proteins, unique and 
reproducible fluorescence readouts, or fingerprints, of proteins were generated 
across all the small molecule features on the SMM. The identity of the small 
molecules of the array were not known a priori due to the synthetic strategy used, 
necessititating a big deconvolution effort to identify the molecules at every 
address on the array (such information is useful in mapping protein-ligand 
interactions for example). Nevertheless, these reports both demonstrate the 
valuable throughput of SMM as a chemical genetic tool and showcase its 




1.4.2.3.1 Characterizing enzymes using SMM 
  Moving beyond the study of non-covalent biochemical interactions on 
SMM, several groups have reported strategies to fingerprint and characterize 
proteins based on their enzymatic activities.98-104 The methods typically  employ 
fluorogenic coumarin derivatives comprising an enzyme recognition domain. In 
the conjugated state, the small molecule is virtually non-fluorescent; but upon 
enzymatic recognition and catalysis, the coumarin moiety is liberated, restoring its 
fluorescence for easy detection. In one report, small molecule probes were 
successfully designed against four different enzyme classes, namely epoxide 
hydrolases, esterases, proteases and phosphatases and were immobilized in a 
microarray format for parallel analysis against their representative enzymes.99 The 
significant advantage of this approach is the label-free analysis of proteins, setting 
the foundation towards high-throughput profiling of disease states using SMM as a 
potential diagnostic tool. In a similar study, Ellman and colleagues have developed 
fluorogenic peptide substrate arrays for studying protease activity.100        
  Another creative approach by Diamond and Gosalia saw the use of 
nanoliter droplets as microreactors for testing small molecule inhibition against a 
variety of caspases.101 352 small molecules were first printed in spots of glycerol 
which remained hydrated, such that the molecules were freely suspended in 
solution. Subsequently, sequential aerosolized application of a caspase and a 
fluorogenic substrate enabled parallel evaluation  of the inhibition potency against 
all 352 small molecules through direct fluorescence analysis. This strategy 
revealed a caspase inhibitor that showed high potency against all three of the 
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caspase isoforms screened. The greatest advantage offered by this strategy is in 
performing highly parallel solution-based assays on microarrays at extremely low 
reaction volumes (1.6 nL per spot). However, the necessary use of a large amount 
of an organic solvent such as glycerol or DMSO (up to 50% in a reaction) limits 
the applicability of this strategy as most enzymes are not active under these 
condtions. The strategy has since been further explored in profiling serine 
proteases using coumarin-based peptide substrate libraries.102     
1.4.2.3.2 SMM applications involving DNA microarrays 
  The creation process of sizable arrays, involving first the preparation of 
libraries of different molecules and second the addressable display of these 
compounds on slide for parallel screening, has invariably been the greatest 
bottleneck of any small molecule microarray endeavor. One solution to this rides 
on the now routinely used and commercially available oligonucleotide microarray, 
making it cost-effective and attractive to augment this platform with large-scale 
small molecule screenings, with a DNA hybridization-based deconvolution 
approach for identifying small molecule interactions of interest.  
  The PNA approach has also been applied towards enzyme profiling.103,104 
A library of 192 rhodamine-based fluorogenic protease substrates was prepared by 
split-pool combinatorial synthesis with PNA tags.103 These substrates were used to 
profile the proteolytic activity of individual proteases as well as those present in 
clinical blood samples. Dust mite extracts were also screened for proteolytic 
activity and a Derp 1 protease isolated was further screened for inhibitors using 
the PNA-encoded small molecule libraries.104  
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  Our group has pioneered the use of activity-based small molecule probes to 
target multiple enzymes expressed with the coding mRNAs in a ribosome display 
format, followed by high-throughput isolation and identification of subclasses of 
proteins with desired activities using a decoding DNA microarray.105 The use of 
ribosome display is advantageous as it enables in vitro expression of a large pool 
of proteins in a cell-free format, with the incorporation of a unique mRNA tag for 
every member in the protein library. The library was incubated with a biotinylated 
activity-based small molecule probe captured on streptavidin beads. Following 
PCR  amplification of mRNAs associated with the isolated proteins, their identity 
was easily revealed, in parallel, by hybridization on the decoding DNA 
microarray. The strategy was tested against the protein tyrosine phosphatase 
family, where the four targeted enzymes were shown to be cleanly isolated and 
identified on DNA microarray from a mixture of nearly 400 other proteins. This 
approach has furnished a proteomic tool with great promise in genome-wide 
profiling of various classes of proteins en masse.   
  Phage libraries have also been used to genetically encode small molecules. 
Walsh and co-workers have reported a method of tethering phages to small 
molecules for potential high-thoughput chemical screening.106 Sfp phosphopanthe-
theinyl transferase was used to covalently link small molecules monovalently onto 
the peptidyl carrier protein expressed on M13 phage. Five small molecules were 
conjugated to different phages (each with a unique genetic identity) and the small 
molecules, enriched from a typical biopanning experiment against selected target 
proteins, were readily detected and identified using DNA microarray. 
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1.4.2.4 Recent developments 
  New strategies have recently been introduced that expand the scope and 
application of small molecule microarrays. A creative extension by Neri et al. 
have demonstrated the ability to screen multivalent assemblies of small molecule 
against targets of interest.107 The technology uses libraries of organic molecules 
tethered to oligonucleotide tags that contain both a code to uniquely identify each 
small molecule as well as a domain to mediate self-assembly of the library by 
hybridization (Figure 3A). Elegantly, constructing chemical libraries in this format 
exponentially expands the molecular scaffolds that can be generated and screened 
from a single defined library, greatly enriching its size and application. Binders 
with sub-micromolar dissociation constants were isolated against bovine carbonic 
anhydrase and human serum albumin using this strategy. The strategy is well 
suited to the identification of chelated small molecules that could target 
multipocketed enzymes lsuch as kinases, phosphatases and proteases.  
  The most time-consuming step of any array-based application is in the 
preparation and synthesis of diverse sets of samples for screening. Langer and co-
workers have been able to address this by simply printing combinations of 25 
different acrylate, diacrylate, dimethylacrylate and triacrylate monomers on 
pHEMA-coated slides that were polymerized, in situ, to afford 576 different 
acrylate polymers on the array.108 Long-wave UV irradiation initiated 
polymerization and the entire process was carried out in an oxygen-free 
atmosphere. The concatenated small molecules were screened for differential 
ability in supporting embryonic stem cell attachment and proliferation.  
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  Other exciting new developments have also involved the rapid screening of 
small molecules against mammalian cells.111,112 Small chemicals were 
impregnated in discs of biodegradable polymers and assembled in a microarray, 
upon which cells were seeded.109 As the polymer degraded, the compounds were 
released into the cells localized above the spots in a controlled manner. The 
strategy was successfully demonstrated through the administration of toxic 
compounds as well as in the application of a 70-member library for synthetic 
lethal screening on array. Clark et al. have also  developed a cell-based assay to 
evaluate the toxicity of prodrugs when reacted with immobilized P450 on arrays.110 
The P450 and small molecule drugs were encapsulated in sol-gels following 
application of cell monolayers, which were later assessed for lethal effects through 
appropriate staining and conventional microarray scanning (Figure 1.3B). These 
promising strategies thus offer novel methods for performing high-throughput cell 
based assays for analyzing small molecule libraries for potential therapeutic 

























Figure 1.3 Novel strategies in applying SMM. (A) Self-assembling chemical 
libraries.107 (B) Metabolizing enzyme toxicity assay on microarrays.110 
1.5 Project Objectives 
  It is the aim of this thesis to develop novel technologies to functionally 
annotate and characterize enzymes, in particular proteases. The technologies 
developed should ideally be highly scalable and offer a high-throughput insight into 
enzyme biology. By understanding the functional differences of enzymes through 
these methods, it is hoped that one could identify small molecule compounds, that 
could desirably purturbate or modulate enzyme function in vivo, offering rapid 







Inhibitor Fingerprinting of Matrix Metalloproteases 






  This chapter describes a microplate-based approach for high-throughput 
protein fingerprinting. The fingerprints of 7 matrix metalloproteases, representing all 
5 established families of this important class of enzymes were obtained against a 
highly diversified small molecule library. A total of 1,400 peptide hydroxamates were 
individually prepared by systematically permuting both natural and unnatural amino 
acids across the P1’, P2’ and P3’ positions, thereby generating an inhibitor library with 
three-pronged structural diversity. High-throughput screening was efficiently 
conducted in the microtitre plate format, providing a rapid and quantitative 
determination of inhibitor potency across the panel of enzymes. Despite similarities in 
substrate preferences and structural homologies within this class of enzymes, our 
findings revealed distinct patterns of inhibition for each MMP against varied chemical 
scaffolds. The resulting inhibitor fingerprints readily facilitated the identification of 
 38
inhibitors with good potency as well as high selectivity, potentially minimizing 
adverse effects when developing such leads into candidate drugs. The strategy 
presents a novel method for the functional classification of matrix metalloproteases, 
on the basis of the characteristic profiles obtained using the diverse set of inhibitors. 
This approach thus paves the way forward in lead identification by providing a rapid 
and quantitative method for selectivity screening at the outset of the drug discovery 
process. 
2.2 Introduction 
  MMPs share conserved mechanisms and flexible active sites. This presents a 
delicate challenge for the development of compounds that target only aberrant MMPs 
for therapeutic intervention, and exert minimal cross reactivity or side effects.111 
Several MMP inhibitors that were initially selected and optimized on the basis of 
good potency came into extensive phase III clinical trials, only to be discovered 
ineffective because of problems arising from a lack of selectivity.4,112 This raises a 
major impetus to rapidly establish better small molecule inhibitors that not only 
exhibit good potency, but also high selectivity. Ideally such leads should inhibit only 
target MMPs (MMPs -1, -2 and -7) responsible for the relevant disease, while 
minimally affecting any anti-target MMPs (MMPs -3, -8 and -9). MMPs have 
classically been divided into 5 families on the basis of their sequence homology, 
substrate preference and cellular localization (Table 11.1). Such a classification, 
however, provides limited functional information, especially towards aiding the 
design or prediction of potent and selective inhibitors for MMPs. In order to address 
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both these pressing challenges, we present a strategy that facilitates the rapid 
elucidation of inhibitor selectivity and potency through clustered enzyme 
“fingerprints” generated from high-throughput screening of focused inhibitor 
libraries. 
 The general strategy for MMP inhibitor design has involved grafting short 
peptide chains to zinc binding groups (ZBG).113 For our study we have adopted the 
hydroxamate (CONH-O-) group that chelates strongly to the metal center at the 
enzyme active site, and has been exploited in a variety of potent competitive 
inhibitors against this class of enzymes. In this work, we have overcome the inherent 
limitations from traditional mixture-based positional scanning (PS) combinatorial 
libraries, and have created a diverse repertoire of 1,400 individual inhibitor scaffolds 
by adopting the split-pool directed sorting synthesis method (Scheme 2.1 and Table 
11.2). This set of compounds were combinatorially permuted across the P1’, P2’ and 
P3’ positions, providing expansive chemical diversity to target the active sites of 
MMPs (and potentially other classes of metallo-proteins). Assaying different enzymes 
against this library rapidly establishes contributions from each of these defined 
positions towards the overall potency and selectivity of the inhibitors. We herein 
report the dataset acquired by screening a comprehensive panel of seven different 
MMPs with representation from all 5 MMP families. The results were further 
assessed for global activities, specificity and potency as well as hierarchical 
clustering, providing unique insights into inhibitor design and preference within this 
important group of enzymes.  
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2.3 Results 
2.3.1 Library synthesis 
Tagging every microreactor enabled the rapid, tractable synthesis of each 
library member. The chemical synthesis of the eleven succinyl hydroxamates 
(Scheme 2.1), representing the different P1’ substituents in the 1400-member peptide 
library, was performed by my collaborators (see Chapter 8.2). The library was 
prepared in two installments. First a 400-member sublibrary containing a leucine 
sidechain at the P1’ position (represented with single-letter code L) was constructed 
with permutations of all 20 natural amino acids across the P2’ and P3’ positions. An 
additional 1000 member set was constructed with 10 different P1’ warheads 
containing sidechains of both natural and unnatural amino acids (Scheme 2.1). The P2’ 
and P3’ positions in this set was systematically permuted with 10 representative 
proteinogenic amino acids, specifically nonpolar (Ala, Leu, Phe, Trp), charged polar 
(Glu, Lys, His) and uncharged polar (Gln, Ser, Tyr) amino acids. The library design 
forged a novel and comprehensive set of compounds to target metalloproteases, 
featuring both a broad structural coverage for the varying depths and sizes of enzyme 
binding pockets, as well as targeted inhibition through a potent zinc binding group to 
direct these molecules into the active sites. The quality of the final products 
synthesized was confirmed by LCMS of representative samples, indicating most 
inhibitors (>90%) were of correct molecular mass and sufficient purity (>80%). Since 
to a large extent potential impurities were most likely truncated peptides during the 
synthesis, and the final coupling step was the one incorporated the active site directing  
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 Scheme 2.1 Design of combinatorial peptide hydroxamate inhibitor library. (A)  
Library was constructed on rink amide resin using split-and-pool directed sorting 
technology. The P1’ consists of eleven unnatural amino acid made of substituted 
succinyl hydroxamate ZBG (highlighted in pink). Each was assigned a unique single-
letter code (inset). (B) Structures of GM6001, Marimastat and Batismastat.     
 
hydroxamate, the purity of our desired products in the library was considered 
sufficient for the initial primary screening step. 
2.3.2 Inhibitor Fingerprints of MMPs across P1’ 
The profiles of 7 MMPs representing all 5 families of this class of enzymes were 
determined by high-throughput screening against the 1,400 peptide hydroxamates. 
The results are displayed in individual cube plots for each MMP, with the 
representations made to potencies by the size and colour intensity of individual 
spheres (positioned spatially across 3 axes according to their P1’, P2’ and P3’ identities) 
(Figure 11.1). The combined dataset is further presented as a coloured heat-map, 
revealing the unique and discriminating signatures of each small molecule (Figure 
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2.1). The assay was independently reproduced for 100 inhibitors in duplicate to 
confirm that most (nearly 80%) of the inhibitors gave potencies that were consistent 
to the large scale screens (<20% variation in potencies).   
All proteases tested were found to be globally inhibited by scaffolds 
containing a leucine sidechain (L) at the P1’ position. This is consistent with the 
general scaffolds of established hydroxamate-based inhibitors such as GM6001, 
Batimastat and Marimastat that serve as potent and broad-spectrum MMP inhibitors 
(Scheme 2.1).103 The cyclopentyl sidechain (Cp), which is a cyclic mimic of L also 
showed strong potencies with a range of MMPs, as did warheads containing aromatic 
sidechains (phe and long-phe represented by F and lF). Inhibitors containing the  
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 Figure 2.1 (A) Heat-map of 1,400 inhibitors profiled against a panel of 7 MMPs. 
Most potent inhibitors are displayed in red, whilst the least potent inhibitors are 
shown in blue. (B) Magnified heat-map of inhibitors presenting Cp in the P1’ position 
against the panel of 7 MMPs. The colour scale for relative inhibition potency is 
shown inset. P2’ and P3’ substituents were represented by standard single letter amino 
acid codes.  
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sulfone sidechain (Sf) at the P1’ position were potent against MMPs -2, -3, -9 and -13, 
probably as a result of favorable H-bond interactions. Cyclohexyl sidechain (Ch) 
displayed mixed and stronger inhibition potencies against several MMP clusters in 
comparison with other β-branched P1’ sidechains (namely val and ile represented by V 
and I respectively). The latter appeared the least potent, with none of the MMPs tested 
showing significant potency with either of these sublibraries. The polar sidechains 
(e.g. asp, lys and long-ser represented by D, K and lS, respectively) at the P1’ position 
also yielded relatively weak inhibitors. MMPs -8 and -14 were predominantly 
inhibited by only the lF and L sidechains. Apart from these MMPs, the lF sidechain 
was potent against the other deep S1’ pocket enzymes as well, such as MMPs -2, -3, -9 
and -13. Interestingly its natural counterpart, F, exhibited a similar pattern of 
inhibition against the same enzymes, albeit at a lower potency. On the other hand, 
enzymes with a short S1’ pocket, such as MMP-7, were not inhibited by the larger P1’ 
warheads, irrespective of the substitutions made to the P2’ and P3’ positions. MMP-7 
was nevertheless sensitive to two unique hydrophobic P1’ sidechains namely Cp and 
Ch, confirming recent findings (Chapter 6). The Ch sidechain also exhibited potency 
against MMP-3, while the Cp moiety was potent against MMPs -2, -3, -9, -13.  
Certain inhibitor sublibraries with narrower selectivity spectrums were also 
uncovered from the high-throughput screening results. For example, the P1’ sidechains 
containing D and lS were found to perturb MMPs -2 and -3, at the exclusion of all the 
other MMPs screened. K positioned at the P1’ site provided inhibitors that appeared to 
only inhibit MMP-2 under the screening conditions employed.  
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 Figure 2.2 Averaged inhibition contributions across permuted P1’, P2’ and P3’ 
positions. Each bar represents averaged inhibition across inhibitors in the library 
presenting the relevant residue. The error bar denotes the standard deviation across 
each group of inhibitors. The asterisk (*) highlights the residue contributing to the 
highest inhibition average in each graph. 
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2.3.3 Inhibitor fingerprints of MMPs across P2’ and P3’
It was observed that variations across P2’ and P3’ positions contributed more 
subtly to inhibition. This is consistent with both these subsites presenting solvent 
exposed clefts for interaction.114 These positions were nevertheless important in 
contributing to overall selectivity and potency. Even within the broadly potent L and 
Cp sublibraries (Figure 2.1), substitutions in the P2’ and P3’ positions had a marked 
effect on selectivity. In the expanded heatmap of the sublibrary containing the Cp 
sidechain at the P1’ position, these contributions are more clearly visualized (Figure 
2.1B). On average, inhibitors presenting aromatic sidechains (F, W and Y) in the P2’ 
position displayed improved inhibition potencies, as did residues with S or A at the 
P3’ positions (Figure 2.2). This is consistent with various reports describing favorable 
contributions of similar positions and residues to overall inhibitor potencies.114-115
2.3.4 Averaged inhibitor fingerprints 
In order to better visualize contributions across the different positions, 
potencies from each of the P1’, P2’ and P3’ sidechains in the inhibitor library were 
averaged and graphically presented (Figure 2.2). The error bars reflect the standard 
deviation of the results, to serve as an indication of variance within each combined 
set. Evidently, the greatest margins of difference in potency came from substitutions 
at the P1’ site, reinforcing this position’s importance to potency. Besides previously 
mentioned residues that marginally contribute to overall potency, there otherwise 
appeared to be insignificant potency changes from the P2’ and P3’ position across all 
the MMPs. Interestingly, this was somewhat different from the findings where single 
amino acid were varied to the scaffold at the same positions; closer examination of 
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individual inhibitor fingerprints clearly indicate measurable effects on inhibition 
potency as well as selectivity across MMPs (Figure 2.1b). This analysis thus 
highlights that though insight may be drawn, valuable information may also be lost 
through combined analysis and averaging. This underscores the importance of 
assaying scaffolds independently using individual peptides rather than mixture-based 
peptide libraries (including position scanning libraries).116 Our strategy accordingly 
enables accurate and informed selections of molecules with desired activities from 
within a combinatorial library (vide infra).  
2.3.5 Cluster analysis of MMPs 
To compare primary sequence information of the MMPs with the specificity 
results obtained through inhibitor profiling, we hierarchically clustered MMPs across 
both these dimensions. Protein sequences were retrieved for 17 MMPs (including the 
7 selected for this study) and clustered with ClustalW (Figure 2.3A). The cladogram 
obtained confirmed traditional classifications of MMPs based on sequence homology. 
MMPs -2 and -9, both gelatinases were grouped closely together. Stromelysins, 
MMP-3 and MMP-10, were also clustered in the same clade, as were the membrane-
type metalloproteases, MMPs -14 and -15. The MMPs were then clustered according 
to the inhibitor fingerprints obtained against the 1,400 inhibitors. This produced a tree 
diagram as displayed in Figure 2.3B, representing classification on the basis of 
functional inhibition of the MMP panel. This analysis revealed that MMP-2 was the 
most distinct in its inhibition profile. MMPs -9 and 13 formed a sister pair, as did 
MMPs -8 and -14, highlighting the similarity in inhibitor preference amongst these 
enzymes, and across traditional family clusters. Clustering was also performed for 
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averaged potency data from the P1’ position (Figure 2.4). This provided a relatively 
unchanged cladogram. MMP-2 was again delineated from the other MMPs. MMPs -8 
and -14, and MMPs -9 and -13 were further grouped as sister pairs, suggesting that 
contributions across P1’ positions were of predominant importance in overall 
clustering.  
This inhibitor-based classification provides a useful way of looking at MMPs, 
with functional relevance when attempting to design specific inhibitors against 
specific members of the family. This initial model provides preliminary relationships 
by incorporating inhibition dependent profiles for MMP classification. This 
classification is distinct, indicating that inhibition selectivity and associations may not 
be sufficiently predicted from known substrates or primary sequence data alone. 
Similar conclusions have also been drawn through profiling cysteine proteases using 
positional-scanning peptide substrate libraries.25
The averaged P1’ data was also clustered across the 11 residues (Figure 2.4). 
This clearly discriminated the more potent residues (Cp, L, lF and Sf) from the other 
P1’ sidechains. The generally weaker sidechains (I, V, K, D and lS) were grouped 
close together, with the mixed inhibitors (Ch and F) showing a closer relationship to 
one another relative to the other groups. This is consistent with earlier analysis 
relating contributions of these P1’ sidechains to overall potency.  
 49
 Figure 2.3 Cladograms of MMPs based on (A) Sequence homology and (B) Inhibitor 
fingerprints.  Sequence data for each MMP was obtained from MEROPS and image 
was produced using the ClustalW software. Approximately 170aa for the active site of 
each protein were aligned and visualized by TreeView 
(http://taxonomy.zoology.gla.ac.uk/rod/treeview.html). MMPs used in this study are 
shown in blue and bold. For Figure 2.3B, the 7-member MMP panel was clustered 
according to the complete inhibitor fingerprints obtained. Average linkage clustering 
was performed.  
2.3.6 Top 100 analysis 
We picked the best 100 inhibitors against each MMP and used Venn diagrams 
to evaluate the distributions of these hits across the 7 MMP panel (Figure 2.5). These 
represented inhibitors that displayed relative inhibition potencies of at least 75% 
against respective MMPs. Despite a considerable overlap in the inhibitors appearing 
in multiple top 100 lists (there were 375 unique scaffolds from the 700 total selected), 
we were able to identify individual inhibitors with varying degrees of selectivity 
against the MMPs. This included a total of 198 inhibitors (approximately 47.5% of 
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the unique inhibitors scaffolds) that were selective against specific MMPs. The 
identities and specificities of these inhibitors are listed in Table 11.3A. We also 
uncovered inhibitors from this subset that exhibited potency against more than 1 
MMP. Although no single inhibitor was potent against all 7 MMPs, a total of 13 were 
found to be potent against combinations of 5 MMPs (Table 11.3B). 10 of these 
inhibitors presented L in the P1’ position, confirming earlier analysis of this sidechain 
as potent in broad range MMP inhibitors. We also found that a total of 86, 47 and 31 
inhibitors from the top 100 set that targeted combinations of 2, 3, and 4 MMPs 
respectively (Figure 2.5B).    
 
Figure 2.4 Hierarchical clustering across the P1’ position. Image was generated using 
using Cluster and presented in treeview (http://rana.lbl.gov/EisenSoftware.htm). Average 
linkage clustering was performed both across the MMP panel (tree in black) as well as 
across the P1’ substituents (tree in pink).   
 51
 
Figure 2.5 Distribution of top 100 inhibitors. (A) Venn diagrams illustrations of top 
100 inhibitors against each MMP. (B) A total of 198 inhibitors out of the 375 unique 
scaffolds in the top 100 set were selective against individual MMPs. 13 broadly 
selective inhibitors were uncovered that appeared in the top 100 in at least 5 MMPs.  
 
2.3.7 IC50 measurements of selected inhibitors  
For a more quantitative determination of the inhibition potencies, we subjected 
11 inhibitors with differing specificity profiles to complete IC50 evaluation with the 
MMP panel (Table 2.1 and Figure 11.3). We selected inhibitors on the basis of broad-
range as well as narrow range potencies, as well as from results determined from the 
Top 100 classification. We also attempted to characterize several inhibitors that 
appeared to discriminate only a single target or anti-target MMP. We predominantly 
selected representation from P1’ Cp and L sublibraries for a more focused analysis on 
a subset of the whole dataset, which is by no means exhaustive. Notwithstanding, we 
were able confirm with IC50 measurements the predicted selectivity patterns for most 
of the inhibitors screened. The analysis shows that certain inhibitors were found to 
give high potencies across a wide range of MMPs. This included inhibitors like Cp-
W-A and Cp-Y-L that provided low nanomolar potencies against most of the MMPs 
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screened. Cp-Y-L was also found to be one of the most potent inhibitors evaluated 
against the MMP-7 target, providing a strong IC50 value of 52.3 nM. Various other 
potent inhibitors were also uncovered against other MMPs. For example L-I-G was 
found to be highly potent against MMPs -8, -9 and -13 with IC50 values of 8.8 nM, 
12.9 nM and 7.2 nM respectively.  
Table 2.1 IC50 of selected inhibitors against panel of enzymes. 11 inhibitors identified 
from the library were subjected to IC50 analysis for more detailed evaluation against 
all 7 MMPs. The IC50 values obtained using a dilution series of each inhibitor is 
tabulated (shown in bold with error margins) together with the inhibition potencies 
obtained from the high-throughput screening (shown in italics). The molecules are 
grouped as follows: Selective inhibitors in green, potent broad range inhibitors in red, 
and non-potent inhibitors in blue; a commercial broad spectrum MMP inhibitor, 
GM6001, is shown in pink. Instances where the inhibition potencies were not 
predictive of the IC50 values obtained are underlined. (n.d. – not determined).  






























  2. Cp-A-L >2000 (17.8) 
>2000 
(23.6) 
116* ± 29 
(84.0) 
963 ± 316 
(39.1) 
383 ± 72 
(51.3) 





























  4. Cp-A-F >2000  (34.0) 
>2000 
(27.6) 










  5. Cp-W-A 203 ± 62 (82.2) 
299 ± 40 
(100)
173 ± 39 
(83.0) 
34 ± 11 
(64.8) 
11 ± 4.6 
(99.2) 
33 ± 12 
(93.8) 
199 ± 36 
(67.4) 
  6. Cp-Y-L 472 ± 222 (55.0) 
165 ± 29 
(100) 
52 ± 25 
(92.7) 
209 ± 153 
(46.3) 
39 ± 16 
(82.5) 
12.4 ± 8.6 
(100) 
223 ± 45 
(29.5) 
  7. L-I-G 167 ± 125 (81.0) 
501± 65 
(80.1) 
138 ± 121 
(77.2) 
8.8 ± 4.9 
(99.5) 
11 ± 3.8 
(94.9) 
7.2 ± 3.3 
(84.1) 
81 ± 12 
(83.2) 
  8. L-V-L >2000  (0) 
569 ± 85 
(14.2) 
98 ± 35 
(67.8) 
451 ± n.d. 
(16.5) 
574 ± 90 
(30.1) 
62 ± 41 
(4.9)


















  9. L-V-M 1900±980 (0) 
286 ± 81 
(25.1) 
98 ± 35 
(69.2) 
275 ± 235 
(8.3)
223 ± 50 
(35.9) 
463 ± n.d. 
(6.2)
133 ± 17 
(16.2)



































17 ± 4 
(>90) 
27 ± 4 
(>90) 
41 ± 14 
(>90) 
1.4 ± n.d. 
(>90) 
4.1 ± 1.0  
(>90) 
3.2 ± 2.3 
(>90) 




Narrow range inhibitors uncovered included members from the Cp sublibraries 
presenting with A in the P2’ position that conferred 2 to 3 fold greater selectivity 
towards MMP-7 (a target MMP), over the other MMPs screened. Specifically Cp-A-
L, Cp-A-Y and Cp-A-F all gave low nanomolar inhibition potency, 116 nM, 168 nM 
and 172 nM respectively. 
Another inhibitor, F-E-A was also selective towards MMP-13 (a non-target 
MMP) at an IC50 of 164 nM.  GM6001 was also screened alongside the selected 
inhibitors and provided IC50 values consistent with those previously reported with 
these enzymes.117 As expected, selected inhibitors presenting V and I at the P1’ 
position exhibited relatively weak IC50 values that were too low (>2 μM) to be 
determined accurately from the assay set up. We further observed that apart from a 
few exceptions, there was very good correlation with the relative potencies in the 
high-throughput screening and the IC50 values determined. 
2.3.8 Docked positions of selected inhibitors 
Selected inhibitors were also employed for docking analysis with two 
representative MMPs. MMP-7 a short P1’ pocket enzyme and MMP-2, a long P1’ 
pocket, were used to highlight the binding mode of the inhibitors to the active sites of 
the enzyme in Figure 2.6 (i.e. a broad-range inhibitor Cp-Y-L and a narrow-range 
inhibitor Cp-A-F) and Figure 11.2. As would be expected, the optimized docking 
configuration of the inhibitor/enzyme complexes revealed the inhibitors adopted an 
extended conformation, comfortably fitting along the substrate binding groove in the 
enzyme active site (Figure 2.6). The hydroxamate group from the inhibitor was 
observed to chelate to the bound zinc atom while the P1’ sidechains fitted nicely into 
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the S1’ pockets. The potential docking configurations of potent MMP-7 inhibitors Cp-
A-F and Cp-Y-L are displayed, indicating that both fitted nicely into the active sites 
of the MMP-7 (Figure 2.6A and Figure 2.6B). Docking of Cp-A-F with MMP-2 was 
unsuccessful, potentially because of low binding affinity as indicated from the IC50 
analysis (Table 2.1). The docking result for MMP-2 with Cp-Y-L, as shown in Figure 
2.6C, indicates smaller sidechains at the P1’ (such as Cp) binds well to the 
unobstructed and deep S1’ pocket of MMP-2. In addition, longer P1’ sidechains (i.e. 
L), also docked successfully (Figure 11.2), thus accounting for the relatively high 
potency of these two side chains. It was further observed that the P2’ and P3’ positions 
of the inhibitor bound to solvent accessible regions of the protein, partially accounting 
for the lower degree of selectivity observed from these sites. They could however 
contribute to overall inhibition potency through the formation of hydrogen bonds or 
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Figure 2.6 Docking configurations of selected inhibitors with MMPs. Both a potent, 
selective (Cp-A-F) and potent broad-spectrum inhibitors (Cp-Y-L) were used to 
display potential binding configurations in the enzyme active site of MMP-7 (short S1’ 
binding site) and MMP-2 (deep S1’ binding site). (A) MMP-7 complexed with Cp-A-F 
and (B) Cp-Y-L. IC50 profiles with these inhibitors were shown (inset). (C) MMP-2 
complexed with Cp-Y-L. IC50 profile with this inhibitor were shown (inset). The zinc 
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2.4 Discussion 
It has been a long-standing goal to develop inhibitors against MMPs as they 
have been implicated in many human diseases.118 Various global formats have been 
introduced in attempts to provide a clear mechanistic and functional understanding of 
MMPs.113, 119-131 They include degenerated peptide libraries for the identification of 
potential MMP substrates,119 the development of activity-based fluorescent probes to 
target these enzymes in vivo,120-121 the use of various computational methods for the 
discovery of enzyme inhibitors113, -122 123 and structure-activity studies for inhibitor 
design.124 Other efforts to probe MMP substrate specificity through phage display,125-
126 synthetic peptide substrates127-128 and mixture-based libraries,129-130 however, did 
not always provide accurate models when compared with native substrates,131 limiting 
the immediate utility of such approaches towards inhibitor design and development 
(Table 11.4).  
The present work describes, to our knowledge, the first large-scale inhibitor 
library for comprehensively and systematically addressing variations in inhibitor 
selectivity across metalloproteases. By adopting a high-throughput screening format 
and a focused library of inhibitors, we were able to readily obtain unique inhibitor 
fingerprints against a panel of 7 representative MMPs. Further analysis of the 
inhibition patterns revealed unique clusters that were unlike traditional MMP 
groupings. This new classification on the basis of inhibitor selectivity has significance 
towards future design of targeted inhibitors against specific MMPs. Moreover, it was 
established that MMPs from different families could exhibit very similar inhibitor 
fingerprints, indicating that they could potentially be targeted with very closely 
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related inhibitors. This was so in the case of MMPs -8 and -14 as well as MMPs-9 and 
13. Computational methods have also revealed similar similarities across MMP active 
sites. Lukacova et al. have examined a range of MMPs active sites using force field 
interactions, which revealed similarities between MMPs – 3 and 7 as well as amongst 
MMPs -2, -3, -8 and -12 and MMPs -3, -7, -8 and -12.122 This correlates well with our 
own findings with MMPs -3 and -7 clustering close to one another (Figure 2.3). 
Consistent with what has been established across MMPs, we found that the S1’ pocket 
was the most crucial position in determining inhibitor preference. The P2’ and P3’ 
positions were nevertheless important in conferring inhibitor selectivity across various 
MMPs. 132-133       
 One clear benefit of our strategy is the design of a combinatorial library with 
discrete sequences. For synthetic convenience, positional-scanning libraries have 
traditionally been applied for high-throughput studies in examining global preference 
towards effectors or inhibitors.134 This method assumes that contributions across 
different positions of the library do not significantly contribute to potency. Though we 
were able to overcome the synthetic challenge in creating a whole library of uniquely 
defined inhibitors, we simplified our data analysis in the same way that synthesis is 
simplified in positional- scanning libraries, by averaging effects from alternative 
positions. Interestingly consolidating our data in this manner led to a significant loss 
of information, especially in deciphering selective inhibitors for a group of highly 
similar and conserved enzymes (Figure 2.3 could very well represent results from a 
positional-scanning library designed for the same purpose), underscoring the 
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limitation of positional-scanning libraries in the accurate determination of closely 
related inhibitors.  
 Our detailed analysis enabled us to identify inhibitors that were both potent 
and selective against various MMPs. It is important to establish selectivity at the early 
screening stage especially in providing a clear understanding of undesirable off-target 
effects of these inhibitors. This could be factored in during lead optimization to 
maximize success in drug development, especially amongst a highly similar group of 
proteins like the MMPs. Where possible it would be desirable to screen with a highly 
pure and well characterized library. It is noted that in our study variations across the 
small molecules within the library set (for examples minor differences in purity and/or 
concentrations) as well as standard buffering conditions (which may not be perfectly 
optimal for every enzyme screened) could contribute to differences to the enzyme 
fingerprints obtained.   
However by validating a subset of our data through secondary screening, we 
have uncovered a wide range of narrowly as well as broadly selective inhibitors 
against MMPs. Further analysis has also led to the discovery of certain scaffolds that 
also exhibit good potency with several MMPs and may be developed and optimized 
for greater selectivity in the design of selective and potent MMP inhibitors for 
therapeutic applications. Significantly we identified potent chemical scaffolds, 
specifically within the Cp and L sublibraries, that could selectively inhibit MMP-7, a 
known target in pancreatic cancer and intestinal adenoma.4 We also identified several 
broad spectrum inhibitors with low nanomolar potency against a variety of MMPs. 
Notably, we have so far only explored a subset of the complete screening results in 
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detail, and there are potentially many other inhibitors characterized within our dataset 
with desirably tuned selectivity.  
2.5 Conclusion 
In conclusion, we have presented a strategy for the discovery of selective and 
potent MMP inhibitors. We find that with a modest library size of 1,400 inhibitors, we 
were able to functionally discriminate this highly homologous group of enzymes 
through the use of novel fingerprinting experiments using inhibitors that address not 
only their potency, but more importantly their selectivity. This potentially provides a 
good therapeutic resource in the combinatorial treatment of cancers and other 
disorders, as well as in further structure-activity assessments for improved drug 












This chapter describes the development of a generic method for the large-scale 
functional characterization of enzymes in a microarray. Poly-L-lysine and amine 
reactive slides were coated with fluorogenic substrates sensitive to proteases and 
phosphatases. Patterning enzymes on the slides by robotic printing produced spatially 
addressable, segregated droplets that were simultaneously exposed to the on-chip 
sensors. Multiple enzymes were profiled using this system that provided fluorescence 
readouts across temporal and stochiometric dimensions concurrently on a single 
microarray substrate. This integrated microarray platform may be applied not only 
towards the functional annotation of proteins, but also for rapid agonist and antagonist 
discovery and in performing on chip kinetics.  
3.2 Introduction 
The expanding repertoire of efficacious microarray technologies is in many 
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ways revolutionizing proteomic research. Such wide-ranging impact is attributed to a 
variety of features that make array-based methodologies particularly attractive - the 
most significant of which being the ability to screen thousands of varied interactions 
simultaneously in a miniaturized scale.32 This has given rise to a powerful analytic 
tool for dissecting the complex cellular circuitry, developing minute antibody-based 
platforms for diagnostics and the discovery of lead compounds as novel therapeutics. 
Our present work serves to add rapid enzyme characterization to the ever expanding 
list of microarray applications.135
Most existing microarray methods rely on the detection of strong, non-
covalent interactions between potential “hit” molecules and proteins immobilized on 
the array.136 This has however limited microarray applications to those involving 
simple ligand binding exchanges, precluding key classes of proteins, such as enzymes, 
from being effectively characterized on arrays. Several groups have recently 
addressed this by developing various microarray-based platforms for the high-
throughput screening of different classes of enzymes.137-138
Of the different methods used to detect enzymes, Salisbury et al. and our 
group independently used coumarin-containing enzyme substrate derivatives 
immobilized in a microarray to screen against different hydrolytic enzymes.100,138 
Selective enzymatic cleavage of the fluorogenic coumarins produced distinct 
fluorescence patterns, thus revealing the corresponding substrate-dependent enzyme 
profiles. In a related development, Diamond and Gosalia screened small molecules 
printed in glycerol droplets on a microarray for their ability to inhibit caspase 
activity.101 The caspases were applied followed by a fluorogenic coumarin-containing 
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caspase substrate, via aerosol. Though this facilitated miniaturized profiling of 
enzyme activity for inhibitor screening, the necessary use of low-volatile mediums 
such as glycerol and DMSO limits overall applicability in scenarios requiring 
predominantly aqueous environments. Although the strategy is potentially applicable 
to the screening of multiple enzymes, it has thus far been demonstrated in a “one 
slide-one enzyme” format. Herein, we report a new microarray-based platform for 
potential high-throughput profiling of enzymes (Scheme 3.1). We show that, by 
creating nanodroplets on slides that are precoated with fluorogenic substrates, the 
activity profiles of many enzymes could be readily obtained simultaneously in a truly 







Scheme 3.1 A strategy for rapid screening of enzymes using microarrays. The 
substrates, bodipy-casein conjugate (top) and phosphate-modified coumarin (bottom), 
were used to coat glass slides, and subsequently screen against proteases and 

















  Our approach involved first coating slide surfaces homogeneously with two 
fluorogenic sensors that target phosphatases and proteases. We had previously 
developed a repertoire of coumarin-based sensors for phosphatases, epoxide 
hydrolases and other protease subclasses.139 Phosphate-modified coumarin was used 
herein as a representative of this class of probes. Removal of the phosphate group 
from the coumarin, as a result of phosphatase-catalyzed cleavage reaction, restores the 
fluorescence of coumarin (Scheme 3.1; bottom reaction). The second fluorogenic 
substrate was a commercially available EnzChek Protease Assay™ (Molecular 
Probes, OR, USA) that employs an intramolecularly quenched bodipy-casein 
conjugate. The probes’ fluorescence is recovered upon proteolytic cleavage (Scheme 
3.1; top reaction) by an active protease.  
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3.3 Results and Discussion 
We tested the strategy by first spotting serially diluted trypsin (concentrations 
spanning from 0.3 mg/ml to 0.3 μg/ml) on bodipy-casein coated slides (Figure 3.1). 
The spot intensities obtained were averaged, normalized against background and 
plotted graphically. As low as 10 μg/ml of trypsin was detected using this method and 
saturation was achieved beyond 100 μg/ml. Notably, the same grids printed on 
uncoated regions of the same slide were expectedly blank.  
 
Trypsin Gradient μg/ml 
Trypsin Concentration μg/ml 
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Figure 3.1 A three-fold dilution series of trypsin printed on bodipy-casein coated 
slides scanned after one hour of incubation (top).  The enzyme was spotted in 
quintuplicate.  The intensity profiles are represented by a graphical plot (bottom). 
 
We next screened 37 enzymes (5 phosphatases, 4 lipases, 15 proteases and the 
remaining 12 from diverse classes), together with 2 non-enzymes (Table 3.1) for 
proteolytic activity on the casein-coated slide. For comparison, solution-phased 
microplate experiments were performed concurrently, and the results were normalized 
and presented in Figure 3.2 (top: microplate; bottom: microarray): notably all proteins 
registered comparable fluorescence profiles in both microarray- and microplate-based 
formats, indicating the successful implementation of our enzyme profiling strategy in 
a  microarray. From the results, three proteases, actinase E, subtilisin and ficin gave 
the strongest fluorescent intensities in both the microarray and the microtitre plate 
experiments.∗ A metalloprotease, thermolysin, demonstrated moderate activity even 
in the absence of calcium or zinc incorporated in the buffer. On the other hand, 
cysteine proteases such as 3CL protease, bromelain, papain and chymopapain showed 
weak activity, presumably as a result of the standard buffering conditions used 
throughout (without dithiothreitol), which was perhaps not optimum. Pepsin, an 
aspartic protease also showing weak enzymatic activity in the microarray, was known 
to possess a maximum activity under acidic conditions. While most non-protease 
proteins expectedly registered little or no fluorescence profiles, intriguingly some 
showed weak fluorescence profiles in both microarray and microplate experiments, 
indicating that these false-positive signals may have arisen from trace amounts of 
protease contaminations present in the commercial proteins.   
                                                 
∗ Note that this finding was under the standard buffering conditions, that may be suboptimal for certain enzymes 
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Table 3.1 A set of 39 proteins printed on bodipy-casein coated slides.   
1 Lysozyme 14 α-chymotrypsin 27 Amylose 
2 Acid Phosphatase 1 15 β-chymotrypsin 28 Concannavalin A (control) 
3 Acid Phosphatase 2 16 Papain 29 Alcoholdehydrogenase 2 
4 Alkaline Phosphatase 1 (AP1) 17 Pepsin  30 Carbonic anhydrase 
5 Alkaline Phosphatase 2(AP2) 18 Proteinase K 31 PEP Carboxylase 
6 Alkaline Phosphatase 3 (AP3) 19 Achromopeptidase 32 Pyrophosphatase 
7 Lipase 1 20 Penicillin amidase 33 Trypsin 
8 Lipase 2 21 Esterase 34 Protease 
9 Lipase 3 22 Epoxide hydrolase 1 35 Thermolysin 
10 Lipase 4 23 Acetylcholine esterase 36 3CL Protease 
11 Trypsin inhibitor (control) 24 Epoxide hydrolase 2 37 Actinase E 
12 Bromelain 25 Alcoholdehydrogenase 1 38 Subtilisin 
13 Chymopapain 26 Urease 39 Ficin 
 
*Coloured typeset represents intensities after a four hour incubation: Highly active - 
Red (> 500 RFU), Moderately active - Orange (200-499 RFU), Weakly active - 
Green (50-150 RFU) and Inactive - Blue (< 50 RFU).    
 
 
Figure 3.2 Profiles obtained using the 39 proteins in microtitre plate (top) and on 
microarray (bottom). Normalized values for each protein were entered and visualized 
in TreeView (http://rana.lbl.gov/EisenSoftware.htm). Intensities are represented by a 






Figure 3.3 (A) Microarray images taken at different time points. Samples were 
printed in quintiplicate with the printing pattern shown. (B) The time-dependent 
activity profiles obtained of 8 representative proteins (two from each category-Strong, 
Moderate, Weak and Inactive) was graphically presented. 
 
Furthermore, by scanning the printed slides at different time intervals, we 
were able to map kinetic profiles of each of the proteins tested (Figure 3.3A). The 
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resultant profiles of 8 representative proteins are plotted in Figure 3B. Actinase E 
gave the highest end-point intensity of 970 relative fluorescence units (RFU); its 
initial velocity was determined at 167 RFU/hour.  Subtilisin had however the highest 
initial velocity of 369 RFU/hour with a relatively lower end-point value of 864 RFU. 
It was observed that for almost all the proteins, there was no increase in fluorescence 
signal beyond 4 hours, indicating the reaction was complete. 
Next we screened phosphatases on the coumarin-coated slides both in the 
presence and an absence of a known inhibitor, sodium orthovanadate. The results 
shown in Figure 3.4 were independently validated using microplate experiments. The 
application of 100μM of the inhibitor was found to completely inhibit all three 
phosphatases resulting in no detectable signal on the microarray. 
    Central to our strategy is the application of enzymes onto the reactive array 
surface by robotic spotting. This facilitates the accurate and uniform deposition of 
suitably buffered enzymes, in volumes of approximately 1 pl. Essentially the 
procedure produced segregated droplets, each an independent microreactor. This 
allows a plethora of parameters to be varied, such as pH, buffers, ionic strength and 
presence of additives to be analyzed for individual or many enzymes simultaneously. 
Similarly, huge repertoires of inhibitors or promoters of enzymatic activity may be 
screened concurrently on a single microarray, allowing immediate verification of 
potentially valuable candidates. Though it is a concern in very large arrays that 
staggered protein deposition may attenuate exposure time, shortened printing duration 
may be easily achieved by increasing the number of print heads to up to 48 pins 
loaded on a standard microarray spotter, potentially allowing the arraying of a much  
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 Figure 3.4 Phosphatase-sensitive slides screened against three representative alkaline 
phosphatases (4-6) in the presence and absence of an inhibitor, 100 μM sodium 
orthovanadate.  
 
larger number of proteins, in the order of minutes. Significantly, no-post-spotting 
processing was required, both solving the on-chip diffusion problem that arises when 
microarrays are washed, and minimizing the handling of slides. The strategy was also 
potentially cost-effective; the amount of the fluorogenic substrate required for a single 
reaction in a microplate experiment may be used for thousands of independent 
reactions on the array. For example, a mere 3 μl of the original working stock of 
bodipy-casein (sufficient for 3 microplate-based reactions) was sufficient to coat a 
225 mm2 slide surface on which we routinely performed up to 1260 separate assays - 
with space left over for a theoretical maximum of 5102 nanodroplets (at 350 μm spot 
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spacing). Although we applied the same buffering conditions throughout for 
convenience of testing, the buffers used may be tailored according to the optimized 
requirements for each enzyme. This could allow a more accurate assessment of 
enzyme kinetics and inhibitor selectivity using the nanodroplet microarray approach. 
3.4 Conclusion 
We had previously developed an alternative approach using activity-based 
probes with immobilized enzymes that can also cater to simultaneous profiling of 
many enzymes simultaneously on array.62 The present strategy is potentially more 
advantageous as highly variable conditions may be set up in each microreactor, 
maximizing throughput. There is also a wide range of untapped fluorogenic substrates 
that may be broadly exploited in a cost effective manner on microarrays.140 
Furthermore, the use of enzymes in our strategy did not require their physical 
immobilization on the array and they were thus maintained in solution phase. This 
may provide a valuable feature to study on-chip kinetics of enzymatic reactions 
without having to consider the potential loss of enzyme activities or orientation upon 
immobilization.137 Next generation microarray technology would have to move in line 
with the demands of post-genomic research, propelling the platform to new and 
exiting discoveries in the burgeoning proteomics arena. Our method reported here 
capitalizes on the numerous fundamental advantages provided by microarray-based 
technologies, and allows the potential high-throughput profiling of enzymes under a 
variety of different parameters. It may thus provide a useful tool for future research in 












  The ability to rapidly screen a large library of compounds represents a major 
bottleneck in the discovery of biologically relevant molecules and drug leads. This 
chapter extends the previously discussed nanodroplet platform (Chapter 3) towards 
the quick and cost-effective identification of potent inhibitors of enzymes in a high-
throughput manner. A 400-member library of putative metalloprotease inhibitors was 
screened with two representative metalloproteases. By printing preincubated mixtures 
of enzyme and inhibitors onto a protease-sensitive glass surface, we obtained inhibitor 
fingerprints of thermolysin and collagenase. One of the most potent inhibitor 
discovered was HONH-Suc(2-iBu)-Tyr-Lys-Gly-Gly-Lys(Biotin)-CONH2, which 
displayed a Ki of 2.4 nM against thermolysin. Overall this strategy offers not only a 
rapid method for inhibitor discovery and profiling, but also a viable method for the 
chemical screening of large chemical libraries against various enzyme classes.   
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4.2 Introduction 
Microarray-based technologies have received much attention due to their 
enormous potential in high-throughput screening.141 Of the various platforms 
available, small molecule microarray (SMM) has emerged as an important tool for 
rapid screening of large chemical libraries.82a The critical limitation of SMM lies not 
so much in hit identification as in hit validation. This is because most SMM screening 
methods rely on non-covalent ligand-protein interactions, which invariably introduce 
false positives as a result of inconsequential affinity between the ligand and non-target 
regions of the protein. Without time-consuming validation, it remains unconfirmed 





















We aimed to develop alternative SMM technologies suitable for high-
throughput identification of potential inhibitors that 1) have the ability to directly 
inhibit the catalytic activity of an enzyme, 2) allow immediate identification of potent 
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inhibitors, thus doing away with tedious hit validation processes. Herein, we explore 
one such platform which enables simultaneous evaluation/comparison of hundreds (or 
thousands) of small molecule inhibitors against an enzyme in an activity-based 
manner (Scheme 4.1). By demonstrating its utility herein for profiling potent 
hydroxamate-containing inhibitors  against metalloproteases, we find the approach to 
be well-suited for high-throughput discovery of potential MMP inhibitors. Previously, 
SMM had only been used successfully for activity-based profiling of substrate 
specificity, rather than inhibition, of proteases.138,142 Our present work thus adds 
“inhibitor fingerprinting” to the expanding repertoire of SMM applications.       
Our SMM strategy works by precoating a glass slide with a fluorogenic 
enzyme substrate (bodipy FL casein in our case143), followed by programmed spotting 
of mixtures of the target enzyme and an inhibitor, in individual nanodroplets, to 
predefined locations on the surface. Upon incubation and detection by fluorescence, 
relative potency of all spotted inhibitors is immediately revealed and simultaneously 
compared (Scheme 4.1). This strategy thus takes advantage of the parallel and 
miniaturized aspect of microarray, together with quantitative fluorescence readouts 
attainable from an enzyme-sensitive surface in response to a protease/inhibitor 
mixture (in a dose-dependent manner). Tagging of the enzyme with a fluorophore is 
not necessary, thus allowing it to be evaluated in its native form and in real time. 
Diamond et al. recently developed a SMM system by printing chemical libraries in 
glycerol droplets followed by introduction of an enzyme onto the slide with aerosol 
spray.101 The strategy however has limited applications due to the need of glycerol 
droplets (which inhibit enzymatic reactions and prevent long-term slide storage) and 
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complicated aerosol setups. Our approach needs only a conventional arrayer for 
spotting and standard bioconjugation chemistry for surface derivatization, making it 


































Figure 4.1 Structure of 400-member hydroxamate inhibitors. Diversity was generated 
at P2’ and P3’ positions with 20 natural amino acids. 
 
Thermolysin and collagenase, two well-characterized metalloproteases, were 
chosen in our study, as they exhibit similarity to many vertebrate metallopeptidases, 
in particular to those of the MMP family.121,144 Earlier reports showed that both 
enzymes, like most MMPs, show substrate specificity at P’ sites, with a strong 
preference of hydrophobic residues at their P1’ position.144b Little is known, however, 
about their specificities at P2’ and P3’ positions.121 We therefore synthesized a 400-
member small molecule library with the scaffold HONH-Suc(2-iBu)-P2’-P3’-Gly-Gly-
Lys(biotin)-CONH2, as shown in Figure 1. Each inhibitor in the library comprises a 
succinic hydroxamate “warhead” (a highly potent zinc-binding group against 
metalloproteases), in which the P1’ residue was maintained as isobutyl group 
throughout. The design was based on the structures of Marimastat, Batimastat, and 
GM6001, three broad-spectrum potent hydroxamate inhibitors of MMPs. With 
variations across P2’ and P3’ positions in the library, we aimed to address both the 
potency and selectivity of individual members against different metalloproteases. A 
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flexible linker and biotin were incorporated into each inhibitor for future proteomic 
applications.   
4.3 Results and Discussion 
We applied the nanodroplet strategy to screen the 400 hydroxamate inhibitors 
against thermolysin (Figure 4.2) and collagenase (Figure 4.4). Advantages of the 
approach were immediately evident. First, the entire 400-member library (in 
duplicate) was readily accommodated on a single slide, effectively allowing > 800 
assays to be performed with merely 6 μl of bodipy casein (Figure 2A). Second, the 
relative potency of each inhibitor was immediately revealed by the fluorescence 
intensity generated from its corresponding nanodroplet (small boxes in Figure 2A) 
with more potent inhibitors giving weaker fluorescence signals, thus avoiding tedious 
hit validation. This was unambiguously confirmed by enzyme kinetic experiments 
carried out in microplates on selected inhibitors. Notably, the nanodroplet SMM 
strategy was able to discern slight differences in inhibitor potency. Finally, because 
the enzyme “inhibitor fingerprint” was generated in a single experiment under 
uniform conditions, the heat-maps could be used directly for further SAR analysis to 
address not only potency, but more importantly selectivity, of any given inhibitor 
(Figure 2B).  The dendrograms, before (left) and after (right) cluster analysis, show 
the hierarchical relationships after clustering for each inhibitor against thermolysin 
with regards to its P2’ and P3’ substitutions. In order to validate our results, separate 
experiments were performed in standard microplate format (Figure 4.3). With few 
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exceptions, results obtained from SMM and microplate formats were in good 





Figure 4.2 Results of the nanodroplet inhibitor profiling strategy with thermolysin. 
(A) Microarray image of the 400-member library screened against thermolysin. 
Samples were spotted in duplicate.  Spots of selected inhibitors (labelled by their P2’-
P3’ sequence) with IC50 (in bracket) were boxed. (B) Heat-map representation before 
(left panel) or after Cluster Analysis (right panel) based on inhibition potency (scale 
shown inset).   
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Closer inspection of our data indicated that Cys, Glu and Asp were disfavored 
at both P2’ and P3’ positions. Potent thermolysin inhibitors appear to be those 
containing aromatic (i.e. Trp/Tyr), small (i.e. Ala), hydrophobic (i.e. Leu /Ile), basic 
(i.e. Lys/Arg) and polar (i.e. Gln/Asn) residues in a variety of P2’/P3’ combinations, 
with considerable variations across rows and columns, indicating cooperativity from 
both P2’ and P3’ residues is critical to achieve maximum inhibition.  
 
Figure 4.3 Normalized microarray data across all 400 samples were plotted against 
data obtained using the microplate method. Correlation analysis yielded a Pearson 







Figure 4.4 Results of the nanodroplet inhibitor profiling strategy with collagenase. 
(A) Microarray image of the 400-member library screened against collagenase. 
Samples were spotted in duplicate.  Spots of selected inhibitors (labeled by their P2’-
P3’ sequence) with IC50 (in bracket) were boxed. (B) Heat-map representation before 
(left panel) or after cluster analysis (right panel) based on inhibition potency (scale 
shown inset).   
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Similar to thermolysin, we profiled the Clostridium histolyticum collagenase 
(ChC) against all 400 inhibitors using the nanodroplet profiling strategy (Figure 4.4). 
Interestingly, screening results obtained with collagenase were distinctly different 
from those with thermolysin, with potent inhibitors comprising predominantly 
aromatic (i.e. Tyr/Trp/Phe) and hydrophobic residues (i.e. Leu/Ile) at the P2’ position, 
and Trp at the P3’ position (Figure 4.4). This underlines the potential of our platform 
in detecting subtle substrate preferences amongst different metalloproteases. As with 
thermolysin, a single microarray surface was able to accommodate the entire 400-
member library (with relevant controls) spotted in duplicate. The results from 
duplicated experiments are presented in Figure 4.4B. Inspection of the clustering data 
(Figure 4.4B) demonstrated that aromatic residues (Tyr, Trp, Phe) and hydrophobic 
residues (Leu, Ile) contribute positively to potency at the P2’ position. The tryptophan 
residue at the P3’ position also renders high inhibition potency. This agrees well with 
reported inhibitors for ChC that prefer glycine or leucine in the P1’ position and 
aromatic or hydrophobic functionalities in the P2’ and P3’ positions.145
We went on to perform a more quantitative evaluation of selected inhibitors 
using IC50 measurements (Table 4.1 & Table 4.2). The predictions from the large-
scale nanodrop screens were consistent with the IC50 values obtained (Expanded 
boxes in Figure 2.2A and Figure 2.4A). All inhibitors tested gave IC50 values in the 
nanomolar range. One of the most potent inhibitors identified from our screen is 
HONH-Suc(2-iBu)-Tyr-Lys-Gly-Gly-Lys(Biotin)-CONH2 (IC50 = 9.9 nM; Ki = 2.4 
nM), consisting of Tyr and Lys at its P2’ and P3’ sites, respectively, and was found to 
be 10-fold more potent than GM6001 (Figure 11.4 and Figure 11.5). This finding, to 
 80
our knowledge, provides the first direct evidence of P2’/P3’ selectivity in thermolysin 
inhibitors. It is further supported by inspection of the active site structure of 
thermolysin, showing predominantly hydrophobic S2’ and solvent-accessible S3’ 
pockets.146  
 
Table 4.1 Ki/IC50 values of 6 selected inhibitors from the library together with 
commercial inhibitor GM6001 is tabulated together with results obtained from large-
scale microarray and microplate screens. ESI-MS results are also displayed. (Plots 










Leu-Phe 144.5 NDa 916.5 
(917.1) 
Ser-Ser 176.7 104 830.2 
(830.9) 
Ser-Tyr 107.3 ND 906.2 
(907.0) 
Tyr-Gln 38.5 ND 947.3 
(948.1) 
Tyr-Asn 33.1 ND 933.3 
(934.1) 
Tyr-Lys 9.9 2.4 947.3 
(948.1) 
GM6001 23.9 25.2 - 
aND = Not determined 
 
Table 4.2 IC50 values of 3 inhibitors selected from large-scale microarray screens. 
ESI-MS results are also displayed. (Plots displayed as Figure 11.6)  
P2' - P3' IC50 / nM ESI-MS found 
(calculated) 
Ser-Tyr 124.8 906.2     
 (907.0) 
Tyr-Asn 45.9 933.3      
(934.1) 





In conclusion, we have developed a nanodroplet SMM strategy for high-
throughput profiling of inhibitors against metalloproteases, potentially extendable to 
other enzymes. It enables potent and highly selective inhibitors to be directly 
identified without the need of time-consuming hit validation. Our strategy thus 
provides a new tool in the ever expanding SMM technologies for the inhibitor 








Activity-Based Fingerprinting of Metalloproteases 





This chapter describes the application of “Click Chemistry” for the facile 
synthesis of various affinity-based hydroxamate probes. These probes enable 
generation of activity-based fingerprints of a variety of metalloproteases, 
including matrix metalloproteases (MMPs). This has applications towards protein 
profiling, detection and discovery in proteomics experiments. Each protein tested 
was shown to provide distinctive labelling fingerprints in gel-based assays. The 
probes were also tested with protein microarrays, and were found to positively 
label only metalloproteases, providing a method for high-throughput functional 
annotation.   
5.2 Introduction 
  Despite their well-documented pro-tumorigenic actions, only three MMPs, 
namely MMP-1, 2 and 7 have thus far been experimentally validated as potential 
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cancer targets. Another three (i.e. MMP-3, 8 and 9) have recently been classified 
as antitargets due to the key role they play in normal tissue homeostasis. With the 
precise biological functions of other human MMPs remaining largely unknown, 
the development of novel chemical and biological methods capable of high-
throughput identification and characterization of MMPs has become increasingly 
urgent.  
  Activity-based profiling, originally developed by Cravatt et al,147 is one 
such technique that has recently been adapted for the study of metalloproteases 
including MMPs.148 ABP works by selectively targeting enzymes of choice from a 
crude proteome, in  an activity-based manner, using the so-called activity- and 
affinity-based small molecule probes. In  the case of MMPs,  small molecule 
probes possessing a) a hydroxamic acid recognition moiety known to chelate to 
the actives-site zinc of MMPs (as well as other zinc-containing proteins such as 
Thermolysin and Collagenase), b) a photolabile group (usually benzophenone or 
diazirine) capable of covalent crosslinking to the target enzyme, and c) a 
fluorescent/affinity tag for easy visualization/isolation of the cross-linked enzyme, 
have been successfully documented.121,149 Furthermore, in cases where a repertoire 
of probes having different recognition elements are available, one can obtain the 
“activity-based fingerprint” of the target enzyme, which reveals not only affinity, 
but more importantly specificity, of the enzyme/probe complex.150 Most activity-
based profiling experiments have been routinely carrried out in gel-based 
experiments.  Recent extension of ABPs into protein microarray has promised 
even higher throughput, as well as miniaturalization, in future enzyme assays.151  
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5.3 Results and Discussion 
5.3.1 Probe Synthesis 
  As shown in Scheme 5.1, we have previously developed MMP probes were 
peptides containing an N-terminal hydroxamic acid. Despite simplicity in their 
chemical synthesis, these so-called “left-handed” probes suffer a major drawback 
in that they bind to MMPs with relatively low affinity, making them less suitable 
for sensitive detection of MMPs from a complex proteome. In this chapter, we  
adopted second-generation “right-handed” probes assembled by “click chemistry”, 
2) their application in gel-based activity-based fingerprinting of numerous 
metalloproteases (including MMPs), and 3) the related preliminary microarray-
based experiments, which, for the first time, demonstrate affinity-based probes are 
indeed compatible with protein microarrays for potential enzyme profiling 





























Scheme 5.1 General structures of the 1st and 2nd generation MMP probes. 
 
  “Click Chemistry” is a concept originally introduced by Sharpless et al 
which refers to several classes of chemical transformations that share a number of 
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important properties including very high reaction efficiency (in both conversion 
and selectivity) under mild conditions.152 The Cu(I)-catalyzed 1,3-cycloaddition 
between an azide and an alkyne is one such reaction that has recently been 
explored in the discovery of drugs and materials. Herein, we take advantage of the 
“click chemistry” between an alkyne-derivatized succinyl hydroxamate warhead 
and an azide-containing trifunctional tag for the highly modular and facile 
synthesis of a total of 12 different activity-based probes against MMPs, which are 







Scheme 5.2 General structures of the 12 MMP probes used in this work. Val (A); Leu 
(B); Ile (C); Phe (D); Long-Phe (E); Cyclohexyl (F); Cyclopentyl (G); O-Ph (H); 
Long-OH (I); Lys (J); Asp (K); Sulfone (L). 
 
5.3.2 Application of probes for gel-based protein fingerprinting 
  We next sought to fingerprint different metalloproteases including MMPs 
with our probes. Protein fingerprinting, by its name suggests, is a distinctive 
pattern generated against a panel of focused small molecule probes, which reflects 
the protein’s catalytic activity or binding property. Since our probes were designed 
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fingerprint not only offers invaluable information for decoding the enzymes’ 
physiological roles, but also facilitates the discovery of potent and selective 
inhibitors as potential drugs. A diverse group of different classes of 
metalloproteases were chosen in our experiment, such that they highlight the 
potential of the strategy not only in distinguishing between both close and distant 
members, but also in potential identification and characterization of various 
disease-related enzymes, i.e. MMPs and anthrax lethal factor. In additon, carbonic 
anhydrase, a well-known zinc-binding protein (but not a metalloprotease) was also 
tested.  
  Figure 5.1 displays the results obtained using gel-based fingerprinting with 
the probe library. Notably, we were able to produce distinct and reproducible 
fingerprints for each of these proteins (Figure 5.2), thus providing a unique 
capability of identifying and classifying these proteins according to their labelling 
profiles. Generally the Lys and Ile probes showed the greatest degree of labelling 
and seemed to strongly label nearly all the enzymes tested. The other probes were 
however more discerning in their labelling patterns. It was observed that the 
strongest labelling for MMP-3 was that of Long-OH and Lys probes. This agrees 
well with the known long hydrophobic pocket of MMP-3 that has been previously 
reported to bind designed inhibitors with such long hydrophilic scaffolds.1 MT-1 
MMP also shares a similar long pocket as MMP-3 and is observed to possess 
greater affinity to the Long-Phe as well as the Lys probe relative to the other 
probe scaffolds. The short S1’ pocket of MMP-7 was shown to accommodate both 
the Val and Phe probes. The Asp and Sulfone probes showed the weakest 
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labelling with most of the enzymes, indicating these moieties are generally 
unfavoured for most of the metalloproteases tested. Overall the fingerprints 
enabled different enzymes to be classified according to their similarity. MMP-3 
gave a distinct profile compared to the other enzymes screened. The labelling 
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Figure 5.1 Gel-based fingerprints of 12 probes against 7 metalloenzymes.  The probes 
used are numbered as follows (1) Leu (2) Ile (3) Phe (4) Long-Phe (5) Val (6) 









Figure 5.2 Heat-map fingerprints of 12 probes against 7 metalloenzymes. Strongest 
relative labelling is visualized in red (scale inset). The fingerprints were further 
hierarchically clustered according to their labelling profiles, as shown by the tree 
diagram.  
 
pattern of carbonic anhydrase was similar to that of MMP-7. Both Anthrax Lethal 
Factor and MT-1 MMP show strong, selective labelling with one of the probe 
library set, namely Ile and Lys respectively. Importantly the panel of probes we 
have designed enables sufficient coverage for one enzyme to be distinguished 
from the next. We further confirmed that heat denatured enzymes did not show 
labelling with our probes, indicating that binding was dependent on enzyme 
activity. 
5.3.3 UV Dependent Labelling 
 
A control experiment was performed with a representative enzyme to ensure 
that cross-linking was UV dependent (Figure 5.3). Using the standard conditions 
indicated previously, a 500 nM final concentration of the sulfone probe was used to 
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label 1 μg of thermolysin in the presence and absence of UV irradiation. As would be 
expected, labelling was only observed upon activation with no detectable non-specific 
labelling. 
 
























Figure 5.3 Gel-based labelling in the presence (left) and absence (right) of the UV-
irradiation step.  
 
5.3.4. Concentration Dependent Labelling 
 
5.3.4.1 Protein concentration dependent labelling 
 
A two fold dilution series of thermolysin was prepared from 50 μg/ml to 3.125 
μg/ml. Labelling was performed using the protocol described with the Leu probe at a 
500 nM concentration. The results from these experiments shown indicate that the 











      
  






     































Figure 5.4 An increasing concentration of themolysin was incubated with the Leu 
probe. (A) Gel-images. (B) Densitometric data from the gel-images were plotted to 
show saturation beyond ~12.5 μg/ml of thermolysin.  
 
5.3.4.2 Probe concentration dependent labelling  
A series of probe concentrations ranging from 2 μM to 0.13 μM was used to 
label thermolysin (5 μg/ lane). The representative results obtained with the aspartic 
acid and the sulfone probe are shown below to highlight that labelling was exhibited 
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Figure 5.5 An increasing concentration of probes were incubated with thermolysin. 
(A) Gel Images. (B) Densitometric data from the gel-images were plotted to show 
dose dependent response.  
 
 
5.3.5 Labelling Protein Spiked in Cell Extract 
 
We tested the ability of our probes to selectively label our proteins of interest 
within a complex cellular milieu (Figure 5.6). The results indicate that thermolysin 
was readily labelled by the Leu probe even when diluted over 10 fold in the bacterial 
lysate, demonstrating that future experiments could be performed directly with 






E.coli lysate (μg/ml)                1000    500   250    125    62.5  
                                                 
34 kD
Relative Amount (Thermolysin:Lysate)  1:10     1:5     2:5    4:5    8:5 
 

















Figure 5.6 Labelling of thermolysin in the presence of cellular extract. (A) A range of 
lysate concentrations were used, from 1:10 to 8:5 (Thermolysin: Lysate). (B) 
Densitometric data from the gel-images were plotted.  
 
5.3.6 Labelling on Protein Microarrays 
  We next tested the feasibility of these probes to be used in a protein 
microarray for potential high-throughput discovery of metalloproteases. 
Previously, only activity-based, and not affinity-based, probes have been shown to 
detect enzymes immobilized in a protein microarray. Five different enzymes, of 
which three metalloproteases (i.e. Collagenase, Thermolysin and Anthrax LF), one 
serine protease (i.e. β-Chymotrypsin) and carbonic anhydrase, were spotted in 
triplicate on a glass slide, and subsequently screened with the Leu probe (Figure 
5.7). Results indicate that the probe was in general able to distinguish 
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metalloenzyme activity over other non-metalloenzyme activities, in most cases 
generating positive fluorescence signals only with metalloproteases (e.g. 
Collagenase and Thermolysin), as well as carbonic anhydrase (a zinc-binding 
enzyme), but not with β-Chymotrypsin. Despite several attempts, we were unable 
to detect the fluorescence labelling of Anthrax LF, as well as several MMPs (data 
not shown), on the microarray.  As these proteins were only available from 
commercial sources in very low stock concentrations, we attibuted this to the less-
than-optimal immobilization of the proteins.   
 
 
   
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5 
 
Figure 5.7 Protein microarray of various metalloenzymes screened by the Leu probe.  
Five different proteins were spotted in triplicate: 1. Carbonic anhydrase (300 μg/ml); 
2. Collagenase (300 μg/ml); 3. Thermolysin (300 μg/ml); 4. Anthrax LF (6 μg/ml); 5. 
β-Chymotrypsin (300 μg/ml).      
5.4 Conclusion 
  In conclusion, we have used “click chemistry” to successfully synthesize a 
second-generation library of metalloprotease probes containing succinyl warheads 
with a variety of P1’ functionalities. With these probes, we have been able to 
generate unique activity-based fingerprints against various metalloproteases 
including MMPs and other therapeutically important enzymes such as anthrax LF. 
Such fingerprinting strategies may lead to future identification and 
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characterization of new MMPs, and the development of potential potent and 
selective inhibitors. We have also for the first time shown that affinity-based 
probes may be equally amenable for high-throughput screening of metalloprotease 
activities in a protein microarray. We foresee that such probes could be used in the 















Rapid Assembly of Metalloprotease Inhibitors 





  This chapter describes a rapid method for inhibitor assembly using “Click 
Chemistry”. As in the previous chapter, where “click chemistry” was applied for the 
synthesis of probes, herein a panel of 96 metalloprotease inhibitors was assembled by 
reacting 8 zinc-binding hydroxamate warheads with 12 azide building blocks. Screens 
of the bidentate compounds against representative metalloproteases provided 
discerning inhibition fingerprints, revealing compounds with low micromolar potency 
against MMP-7. The relative ease and convenience of the strategy in constructing 
focused chemical libraries for rapid in situ screening of MMPs is thereby 
demonstrated.  
6.2 Introduction 
MMPs are regarded as important therapeutic targets for a variety of human 
diseases, including arthritis, Alzheimer’s disease, cancer, and heart diseases.4 One of 
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the most widely exploited scaffolds of MMP inhibitors is the peptide-based succinyl 
hydroxamate.114 Inhibitors containing this kind of zinc-binding groups normally 
exhibit broad-spectrum inhibition towards most metalloproteases, rather than to 
specific MMPs alone. This is largely due to the structural similarity in the active sites 
of metalloproteases which possess highly conserved zinc-binding residues essential 
for enzyme catalysis. Therefore, it has been an ongoing challenge to develop highly 
efficient synthetic strategies that allow rapid generation and screening of small 
molecule inhibitors possessing not only high potency but more importantly good 
selectivity towards MMPs.153
Fragment-based assembly, which allows medicinal chemists to explore N2 
possibilities with N+N combinations, is widely employed for high-throughput drug 
discovery.153 It typically involves a two-step process including fragment identification 
and fragment linkage. A number of methods have been developed to assist in this 
process,154 including NMR/x-ray approaches,154a the MS-based tethering strategy,154b 
and “click chemistry” coupled with in situ screening.154c Among them, the “click 
chemistry” approach originally developed by Wong et al. was shown to be a highly 
versatile and effective choice for rapid synthesis and identification of inhibitors 
against a number of biological targets, including HIV protease,155a,b 
sulfotransferases,155c fucosyltransferases,155d protein tyrosine phosphatases,155e 
acetylcholinesterase155f and others.155g However, it remains to be seen whether this 
approach is applicable against other important therapeutic targets, e.g. matrix 
metalloproteases.  
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Herein, we describe the first “click chemistry” approach for the rapid 
synthesis/assembly of a small molecule library based on different succinyl 
hydroxamates and its subsequent in situ screening for identification of candidate hits 
with desirable selectivity. Our approach thus lays the foundation for future 
exploration of more potent and selective MMP inhibitors, in high-throughput, using 
































Figure 6.1 Structure of (top) general hydroxamate inhibitors and (bottom) “click 
chemistry” inhibitors reported herein against metalloproteases. 
 
Our library design was based on the general structure of hydroxamate-based 
MMP inhibitors (Figure 6.1), which were previously shown that (1) hydrophobic P1’ 
residues are in general preferred, (2) a variety of substitutions are tolerated at P2’ and 
P3’ positions, (3) hydrophobic P4’ residues are preferred and sometimes could confer a 
good degree of specificity amongst different metalloproteases.114 As such, a total of 
eight succinyl hydroxamates bearing a variety of alkyl, cycloalkyl and aromatic side 
chains were synthesized as shown in Figure 6.2A. A common alkyne handle was 
introduced to each warhead, facilitating the subsequent assembly with twelve 
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different azides (Figure 6.2B) using “click chemistry”. The azides bear a hydrophobic 
moiety connected via a linker with a varying alkyl length (n = 2-4). By changing the 
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Figure 6.2 Building blocks for rapid assembly of metalloproteases inhibitors. (A) 8 
alkyne-containing warheads. (B) 12 azide-containing building blocks. 
 
binding pocket of a targeted MMP, thus improving both potency and specificity of the 
resulting inhibitors.    
6.3 Results and Discussion 
Next, a 96-member inhibitor library was assembled using “click chemistry” in 
a 96-deep well block.  Each of the eight alkyne warheads was mixed with each of the 
twelve azides (in slight excess; in a tert-butanol/water solution) followed by addition 
of catalytic amounts of sodium ascorbate and copper sulfate.  The “click chemistry” 
proceeded with high efficiency at room temperature for > 12 hours before analysis by 
LC-MS; results indicated, in almost all cases, the complete consumption of the 
alkynes and quantitative formation of the desired triazole products, thus ensuring that 
they may be used directly for subsequent in situ enzymatic screening without any 
further purification.   
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Figure 6.3  Inhibitor fingeprints of 96-member click library screened against (A) 
MMP-7 (B) Thermolysin and (C) Collagenase.  Samples were assayed in duplicate 
and the results were averaged from two independent experiments followed by 
visualization in TreeView.  The most potent inhibitors are highlighted in bright red 
and the relative inhibition scale is shown inset.  
 
MMP-7, is one of the few MMPs that is secreted by cancer cells, and 
contributes to proliferation of intestinal adenomas as well as pancreatic cancer.1 It was 
chosen for this study, together with collagenase and thermolysin that have roles in the 
progression bacterial corneal keratitis and the metabolism of bacillus spp., 
respectively.156 All three enzymes were screened in a high-throughput, automated 
fashion against the 96-member library panel using standard fluorescence assays in 
microplates. The inhibitor potency was evaluated from the reduction in fluorescence 
output when introduced in standard enzymatic assays with quenched substrates. The 























                      









          
Figure 6.4 Inhibitor fingerprints of 3 metalloproteases tested with the inhibitor 
library; I) MMP-7, II) Thermolysin III) Collagenase - represented as “Barcodes”. 
Black: min inhibition; Red: max inhibition.  (b) Screening of “clicked” inhibitors 
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against MMP-7. Heat-map obtained using TreeView displays the inhibition 
fingerprint obtained with most potent inhibitors indicated in bright red. 
 
are displayed in Figure 6.3, The resulting “barcodes” are directly a reflection of an 
enzyme’s inhibition profiles (potency and selectivity) (Figure 6.4). By taking 
advantage of such inhibition fingerprints, it would become possible to characterize 
and group proteins in an activity-dependent manner. Furthermore, such analysis may 
prove useful in distinguishing not only inhibitors that are potent against specific 
enzyme classes, but also those that provide good discriminatory potential, thereby 
minimizing off-target effects of potential drug candidates.  
A broader evaluation of the inhibition profile obtained against MMP-7 (as 
shown in Figure 6.3A) revealed a unique and consistent trend. Hydroxamate warheads 
containing alkyl and cycloalkyl side chains at the P1' position (i.e. L, Ch and Cp, 
respectively) contributed highly to potency of inhibitors against MMP-7.  The 
strongest inhibition was observed for scaffolds containing the latter two unnatural 
cyclic analogues. This correlates well with generic inhibitors against metalloproteases 
such as GM6001 and batimastat that are designed with a small hydrophobic residue 
(Leu), i.e. isobutyl in the P1’ pocket.113 Furthermore, both thermolysin and collagenase 
(Figure 6.3B and Figure 6.3C respectively) do not display such an exclusive and 
distinctive preference for these small cyclic residues.  Our results thus highlight the 
potential of such scaffolds in the design novel inhibitors against MMP-7 and possibly 
other MMPs.  Another observation is that, azides having a 4-carbon linker (n = 4; F8-
11, G8-11 in Figure 6.3A) appeared to contribute negatively to the inhibitor potency, 
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which indicates the linker might be too long to properly accommodate the 
hydrophobic moiety of the azides into P4’ pocket of MMP-7.  
In contrast to MMP-7 that shows almost exclusive inhibition against the 
cyclohexyl, cyclopentyl and leucine warheads, both thermolysin and collagenase 
exhibit a more general inhibition spectrum with the variety of warheads.  
Nevertheless, scaffolds that contain phenylalanine or leucine gave the highest potency 
against thermolysin, whilst those with tryptophan in the secondary fragment (Azide 
building block 6) appeared to contribute consistently to potency for inhibitors against 
collagenase. Our results also revealed two inhibitor scaffolds, E11 and D12, that 
exclusively inhibited the bacterial metalloproteases (thermolysin and collagenase) but 
not MMP-7.   
To unambiguosly confirm the potency of these scaffolds from the preliminary 
screen, two compounds, F5 and G6, representing each of the cyclohexyl and 
cyclopentyl warheads were selected for detailed evaluations (Figure 6.5). These 
molecules were purified and fully characterized by NMR and LC-MS, before being 
evaluated against the panel of metalloproteases to elucidate the relevant inhibition 
constants (Figure 6.5A). As shown in Table 6.1, F5 and G6 indeed inhibited MMP-7 
strongly with a Ki of 1.4 µM and 3.8 µM respectively.  More importantly, these 
inhibitors were 10 to 35 times more potent towards MMP-7 than the bacterial 
metalloproteases tested, demonstrating the potential of the strategy in elucidating 
inhibitors with both good potency and high selectivity against MMPs.  
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Table 6.1  IC50  and Ki evaluation of selected inhibitors against panel of enzymes 
 
 MMP-7 Thermolysin Collagenase 
 Ki/μM IC50/μM IC50/μM IC50/μM 
F5 3.8 12.5 >50 >50 
G6 1.4 6.5 >50 >50 
 
 

































































-5 0 5 10 15 20
[ i nhi bi t or ] / uM
2.7uM subst rat e
1.8uM subst rat e
0.46uM subst rat e
(C) 
(B) 









G6 IC50 = 6.5uM



















F5 IC50 = 12.5uM























Figure 6.5.  Quantitative evaluation of selected inhibitors. (A) Structures of G6 and 
F5. (B) Ki determination of G6 (left) and F5 (right) against MMP-7. (C) Graphs for 
determining IC50 values of G6 (left) and F5 (right) against MMP-7. 
 
 
We performed molecular modelling with G6 - the most potent inhibitor 
identified from our screening, against the MMP-7 active site using the Sybyl™ 
software, on the FlexX suite.157 As would be expected, the optimized docking 
configuration of the inhibitor/enzyme complex shows the inhibitor adopts an extended 
conformation, snuggling comfortably in the enzyme active site (Figure 6.6). The 
hydroxamate group from the inhibitor was shown to chelate to the bound zinc atom.  
The cyclopentyl P1’ side chain fits nicely into the S1’ pocket. As anticipated from the 
original design, the phenolic ring from the azide component appeared to sit in the S4’ 
pocket as well. In addition, a number of favorable hydrogen bonds were also evident 
in the complex. 




Figure 6.6. In silico docking displays the possible binding mode of G6/MMP-7 
complex. The hydroxamic group in the inhibitor chelates with the zinc atom (green 
sphere) in the enzyme active site, with the inhibitor projecting into the S’ pockets of 
the enzyme. Docking was performed using Sybyl v7.2 (Tripos, Missouri, USA) with 
electrostatic surface images generated using WebLab ViewerLite (Accelrys, San 




In conclusion, we have developed a high-throughput strategy for assembling 
and screening MMP inhibitors.  The panel of compounds we have synthesized show 
promise in providing a valuable resource for screening various MMPs and obtaining 
unique inhibition fingerprints. Moreover, we have identified specific scaffolds that 
show good potency and moderate selectivity for MMP-7 over other metalloproteases. 
We anticipate that the unique scaffolds we have uncovered in this study may lead to 






Quantitative Inhibitor Fingerprinting of 






Current methods to identify interactions on small molecule microarrays 
(SMM) introduce false positives that are difficult to dissect from the “real” binding 
events without tedious downstream re-evaluation. To specifically elucidate only 
activity dependent ligand binding interactions, we have developed a technique that 
can be universally applied to present SMM systems. Our method makes use of a dual-
colour application strategy and is based on the simultaneous application of 
differentially treated samples. Overcoming the limitations of slide to slide variation, 
this method directly revealed activity dependent interactions through a one step 
application of protein samples on SMM. Besides providing lead molecules for further 
development, the high-throughput screening results confer activity dependent 
fingerprints for quantitative characterization and differentiation of proteins. Our 
method was first tested using a synthetic hydroxamate peptide library with 1,400 
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discrete sequences permuted combinatorially across P1’, P2’ and P3’ positions. 
Functional profiling across a panel of metalloproteases provided 44,800 datapoints 
within just 8 SMM slides. This data was globally analyzed for activities, specificity, 
potency and hierarchical clustered providing unique insights into inhibitor design and 
preference within this group of enzymes. Quantitative KD measurements performed 
on SMM using one of the enzymes in the panel, Anthrax Lethal Factor - the toxic 
component of a notorious bioterror agent, unraveled several lead micromolar binders 
for further development. Overall, the effectiveness of SMM platform is shown to be 
enhanced and extended using the strategy presented in this work.  
7.2 Introduction 
The challenge of large-scale, quantitative determination of protein-ligand 
interactions in high-throughput calls for the development of microarray-based 
platforms that offer rapid and cost-effective screening solutions.158 One such 
promising technology is the small molecule microarray (SMM), where compounds 
are spatially addressed in high density grids on planar glass substrates, and 
simultaneously interrogated with suitable proteins and other targets.158a This offers a 
cheap and convenient method for the screening of thousands of compounds rapidly, 
and has been successfully used in ligand identification,159 and more recently in 
protein profiling.97,160 The utility of SMM as a routine platform for high-throughput 
discovery has however been limited, primarily because compounds immobilized have 
typically first to be decoded before they could be identified, or high attrition rates 
prevented true binders to be immediately identified (due to non-specific/ false 
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positive/ functionally irrelevant binding), making them difficult to be used in protein 
fingerprinting experiments.161 Herein, we report a novel SMM platform that addresses 
these problems. By employing 1) a target-oriented library of individually synthesized 
compounds in which every member was characterized prior to spotting on the glass 
surface; 2) dual-colour reciprocal protein labelling/ screening strategy; and 3) 
simultaneous and quantitative measurements of multiple protein-ligand binding 
interactions, we were able to immediately and reliably elucidate the activity-
dependent binding profiles of proteins against immobilized chemical libraries en 
masse. A global analysis directly performed with the profiles provided valuable 
insight into protein characteristics, revealing activity-dependent protein fingerprints.  
For the present study, we selected different members of the metalloprotease 
family as our proteins of interest, as enzymes are amongst the most difficult (due to 
their delicate nature) yet valuable (due to their widespread involvement in biological 
processes) classes of proteins to study in a microarray format.162 Metalloproteases, in 
particular, are a group of broad and diverse enzymes critically involved in the 
progression of a variety of diseases and bear important roles in metabolism as well as 
intra- and extra- cellular physiology.162 Modulating these proteins using small 
molecule therapeutics provides a potential handle for the effective management and 
treatment of diseases such as cancer, arthritis as well as combating infections from 
pathogens like botulinum and anthrax.163 This work represents, to my best 
knowledge, the first large-scale quantitative application of protein fingerprinting on a 
small molecule array that enables the functional discrimination amongst closely 
related protein members, fuelling opportunities in drug design and discovery. 
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Various metalloproteases were identified, with representations from human 
pathogens, non-human sources and bacterial origins; including thermolysin, 
collagenase, carboxypeptidase A and anthrax lethal factor (Table 11.5). We designed 
and synthesized a 1400-member small molecule inhibitor library that binds 
metalloproteases in an activity-dependent manner (Scheme 7.1 and Table 11.2); each 
compound features a potent hydroxamate zinc-binding group (red), a permutable 
specificity element for enzyme recognition (blue), a linker to extend the molecules 
from the slide surface (black) and a biotin anchor for site-specific immobilization on 
avidin-coated surfaces (green). Systematic permutation of both natural and unnatural 
amino acids across the P1’, P2’ and P3’ positions (key binding sites of most known 
metalloproteases) in the inhibitors provided a rich diversity of 1,400 discrete and 
tractable sequences for protein fingerprinting. The chemical synthesis of the library 
was based on the previously optimized solid-phase approach by adopting the 
IRORI™ split-and-pool directed sorting technology.164 Taken together, our design 
features systematic comparisons across pure scaffolds, circumventing limitations of 
screening resolution and accuracy when using mixture-based libraries.165 The library 
was subsequently spotted on an avidin-coated glass slide to generate the 
corresponding metalloprotease-targeting small molecule microarray in which the 
identity of every spot was known a priori. As only appropriately biotinylated 
members of the library installed with the hydroxamate moiety would show significant 
binding to metalloproteases, the immobilization and presentation step of molecules on 
the microarrays could potentially filter away some of the impurities within the library. 
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Scheme 7.1 Design of the 1,400-member hydroxamate peptide inhibitor library. The 
P1’, P2’ & P3’ positions in the inhibitor sequence were based on the standard protease 
nomenclature.  
 
purity of at least 80% of the library was greater than (90%). We assume that the 
impurities do not greatly jeopardise the screening profiles obtained.   
To minimize false positives and ensure most data generated in SMM can be 
used directly for protein fingerprinting, we developed a dual-colour reciprocal 
labelling/ screening strategy, in which both the active and denatured forms of a target 
protein (e.g. thermolysin) were minimally labelled with two spectrally distinct dyes 
(Cy3 and Cy5) reciprocally and applied simultaneously to the same SMM (Figure 
7.1). This provides a dual-channel screening strategy in which one channel 
(containing denatured protein) is used as an internal control for direct and immediate 
elimination of non-specific binding effects from the positive channel (containing 
active protein). By inverting the active/ control channels, dye bias (from protein 
labelling) is further eliminated ensuring that profiles generated are both activity-
dependent and highly reliable.  
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Active      Inactivated    Active  Inactivated 
Figure 7.1 Reciprocal labelling and application strategy for activity dependent high-
throughput microarray screening. Cy3 labeled protein is false coloured in green, while 
Cy5 labeled protein is false coloured in red. Normalized signals from the active 
protein channel constitute real binding profiles on the SMM. Non-specific binding 
from denatured or inactive proteins can be readily identified and corrected (i.e. 
exclamation point).    
7.3 Results 
7.3.1 Inhibitor Fingerprinting with Thermolysin on SMM 
High quality and reproducible results were obtained, as shown in Figure 7.2 
for thermolysin. Routinely, strong correlations were obtained between duplicate spots 
on the same slide (r > 0.98) and across independent slides (r > 0.96). After 
optimization, heat inactivation almost completely eliminated any binding signal on 
the slide, confirming that the spot patterns observed were due to protein activity 
(Figure 7.2A). The intensity values arising from equal quantities of Cy3 and Cy5 dyes 
were determined to be equivalent on our scanning systems (Figure 7.3) enabling 
direct averaging and combination of the data obtained from both channels without the 
need for scaling or normalization. Though correlation was high across reciprocal 
channels (r = 0.92), several points reproduced poorly across the duplicated 




Figure 7.2 Dual-colour reciprocal labelling/ screening strategy. (A) Microarray 
images obtained with Thermolysin. The Cy3 channel is false coloured in green, while 
the Cy5, in red. (B) Scatter plot of thermolysin results from reciprocal experiment. 
Data was filtered to remove aberrant points (indicated in pink). (C) Cube plot with 
1,400 inhibitors. Each inhibitor is represented by spheres plotted according to the P , 
P  and P  identities in the cube plot. Relative potency is indicated by both the colour 
spectrum (cyan - least potent, red - most potent) as well as by size of the sphere (small 








filter (Figure 7.2B). Averaged results from reciprocal experiments for the 1,400 
member library were visualized as a cube plot in Figure 7.2C. In order to correlate 
results obtained on the SMM platform with traditional systems, we performed 
solution-phase screening of the 400 member P1’ L sublibrary in microtitre-plate 
format. Despite fundamental differences of solution-phase inhibitor screening over  
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Figure 7.3 Graphs displaying equivalent concentrations of Cy3 and Cy5 dye that 
were spotted and scanned. Highly correlated values were obtained across the different 
dye channels. The error bar denotes standard deviation over 5 replicates.   
                 
 
chip-based screening, we observed consistent profiles from both microarray and 
microplate platforms (Figure 7.4). Performing the assay in solution phase involves 
reaction dynamics that may not be perfectly replicable on solid support, due to the 
static visualization of intensity signals on microarray, as well as the modes of ligand 
binding, which is complicated with bulk effects, slower kinetics and ambient analyte 
effects.166 Nevertheless a consistent fingerprint was obtained with a Pearson 
correlation of 0.55, with a patterned similarity of the data obtained across both 
platforms. Of note, under varying treatments and washing conditions of the SMM the 
correlations fluctuate. This highlights the importance of careful optimization and 
handling procedures to extract the most accurate and meaningful activity-dependent 
profiles using SMM. Nevertheless this comparison confirmed the activity-dependence 
of the profiles obtained using SMM, as well as showcased its potential for rapid 






Figure 7.4 The 400-member P1’ L sub-library was screened using microplate and 
compared with the fingerprint obtained using SMM. The most potent inhibitors are 
displayed in green, according to the scale shown inset.  
 
7.3.2 Inhibitor Fingerprinting with Enzyme Panel on SMM 
Having optimized the platform and testing its capability with the model 
enzyme thermolysin, we went on to characterize various other metalloproteases. 
Using the same dual-channel screening approach, we applied these enzymes in 
reciprocal channels on the 1,400 member hydroxamate SMM. Each enzyme was 
profiled as earlier described with thermolysin, using data from reciprocally duplicated 
experiments. This represented 11,200 independent data points on the SMM that were 
processed for each enzyme, and distilled into the final fingerprint representing the 
1,400 inhibitors. The analysis further enabled false positive or non-specific binders to 
be removed from the analysis through the subtraction of the inactive channel. The 
final activity dependent fingerprints for four different metalloproteases are shown as 
coloured heat maps in Figure 7.2A (and as cube plots in Figure 11.7). Only data that 
was highly discordant between the reciprocal experiments were excluded, as earlier 
described (shown in grey in Figure 7.2A). The presence of 20 mM EDTA (a general 
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metalloproteases inhibitor that works by chelating the metal ion in the enzyme active 
site) was also shown to almost completely abolish the binding patterns with all the 
metalloproteases tested. This confirmed that the fingerprints obtained reflected the 
binding profiles of enzymes only in their truly functional state.  
Each enzyme displayed characteristic patterns with the arrays as shown with 
distinctive fingerprints obtained. The P1’ L side chain, together with F and lF, 
contributed highly to inhibitor potency. The P1’ position is generally regarded as the 
most important in governing selectivity of either substrates or inhibitors amongst 
metalloproteases.162 Closer analysis for thermolysin further revealed a preference for 
F in the P2’ position and W in the P3’ position (Figure 7.2C and Figure 7.5A). In order 
to better visualize the differences across enzymes, the P1’ F sub-library was magnified 
in Figure 7.3A. This highlighted that variations across the P2’ and P3’ positions also 
contributed significantly to binding intensity. This analysis revealed that aromatic 
residues W, Y and F in the P2’ and P3’ positions were greatly favored by almost all the 
enzymes screened. Interestingly, almost irrespective of the P2’ side chain, W at the P3’ 
position was found to have governing importance in inhibitor potency. The 
presentation of small hydrophobic side chains in the P1’ position, and larger aromatics 
in the other prime pockets was encouraging as it agrees well with known potent 
metalloproteases inhibitors including GM6001, Batimastat and Marimastat that also 
present L in the P1’ and F or W in the P2’ position in their scaffolds (Scheme 2.1B). 
Anthrax LF was the most promiscuous metalloprotease in the panel that displayed 
significant affinity with a considerable proportion of the library, warranting further 
investigation (vide infra). Aside the relatively weakly associating lS and Sf P1’ side 
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chains, there was significant binding (as indicated with varying intensities of red) with 
many of the other P1’ side chain categories (Figure 7.5A). The heat-map 
representation further enables direct comparisons across enzymes in the aim to define 
either generic or selective inhibitors.    
                                                                                      
                                     
         
(B) (A) 
Figure 7.5 Activity-dependent fingerprints of I. Thermolysin, II. Collagenase, III. 
Carboxypeptidase and IV. Anthrax LF with the 1,400 molecule hydroxamate inhibitor 
library. (A) Coloured heat- maps displaying intensities with each of the inhibitors 
(scale inset). Inhibitors are sorted by P  > P  > P  according to the order shown inset 
(labelled with single letter amino acid codes).  The zoomed heat-map shows inhibitor 
potencies of the sub-library presenting F in the P  position. (B) Position specific 
scoring matrix (PSSM) representing averaged contributions to potency across P , P  
and P  position. The height of each letter represents the weighted contribution of that 
















properties – hydrophobic/ aromatic (black), acidic (red), basic (blue), polar (cyan), 
hydrophilic (green) and small (beige).  
 
7.3.3 Averaged Inhibitor Fingerprints 
Intensity values for all enzymes were thereafter averaged for each P1’, P2’ and 
P3’ position to globally visualize contributions to potency across the library. The 
results of this analysis were displayed both as position specific scoring matrixes 
(Figure 7.5B) and as bar graphs (Figure 11.8). Here we also confirmed earlier 
findings, where aromatic side chains were found to contribute strongly to inhibitor 
potency. The matrices highlighted that lF and F consistently appeared amongst the top 
3 side chains in the P1’ position for all 4 metalloproteases screened (Figure 7.5B). 
Additionally, across both P2’ and P3’ positions, it was observed that there was a large 
overall contribution from inhibitors bearing W. With peculiar clarity, it was further 
revealed  that side chains classified as hydrophobic/ aromatic contribute significantly 
to the overall potency of these inhibitors, as seen with the “black” residues occupying 
the uppermost positions in the matrices across all 4 enzymes. On the other hand, the 
charged and hydrophilic side chains occupy the lower-most portions of the matrices. 
This correlates very well with established findings against various metalloproteases, 
including those performed for the enzymes included in the panel. A detailed 
comparison of these preferences is performed in the appendix (Table 11.6). It is 
relevant to note that the best inhibitor scaffolds are identified by potent dissociation 
constants, while the best substrates are those that, in addition, provide good 
conversion and thus reversibility of binding.167 Our analysis revealed that apart from 
the conserved residues that have been previously identified in putative substrate based 
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screens, various side-chains (including the unnatural side-chains, Cp and lF) have 
positive contributions towards inhibitor potencies, for future inhibitor design and 
improved efficacy across this class of proteins.  
7.3.4 Top 100 Analysis 
In order to delineate inhibitor selectivity across the panel of metalloproteases 
screened, we picked the top 100 inhibitors within each enzyme and used Venn 
diagrams to evaluate the distribution of these hits across the 4-member 
metalloproteases panel (Figure 7.6). Combining the sample of top 100 hits from all 4 
enzymes provided a set of 260 unique inhibitor sequences (Table 11.7A). We also 
uncovered inhibitors that exhibited potency against 2 or more metalloproteases 
screened. This included 3 inhibitors that were potent against all 4 of the 
metalloproteases screened (Table 11.7B).  
7.3.5 Cluster Analysis  
Hierarchical clustering was performed to group metalloproteases on the basis 
of the activity dependent fingerprint results obtained. The alignments of the primary 
sequences of the metalloproteases used were presented in Figure 11.9. The enzyme 
panel was successfully clustered using the inhibitor fingerprints obtained against the 
1,400 inhibitors to produce a cladogram (Figure 7.7). As expected, Anthrax LF was 
revealed to be the most distinct in its inhibition profile. Carboxypeptidase and 
thermolysin formed a sister pair, highlighting the similarity in inhibitor preference 
amongst these enzymes, and across traditional clan groupings (Table 11.5). This 
relationship was conveniently discernable using the SMM platform, and the utility of 
such a functional classification may not be easily replicated using existing schemes of 
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substrate preference or primary sequence information alone. This inhibitor-based 
classification thus provided a useful way of looking at metalloproteases, with 
functional relevance when attempting to profile inhibitor preference and selectivity 




Figure 7.6 Distribution of the top 100 inhibitors. (A) Venn diagrams representing 
distributions of top 100 inhibitors for each metalloprotease. Regions in green 
highlight uniquely binding potent inhibitors, while regions in orange indicate broadly 
selective potent inhibitors. The values represent total inhibitor numbers in each 
category. Specifically, Anthrax LF presented the largest number of selective inhibitors 
- a total of 75 - from the 100 selected. (B) A total of 169 inhibitors  (65%) out of the 
260 unique scaffolds in the top 100 set were selective against individual 
metalloproteases. 3 broadly selective inhibitors were uncovered that bound potently 
with all 4 metalloproteases. We also found that a series of 45 and 43 inhibitor 
sequences from the top 100 lists that targeted combinations of 2 and 3 
metalloproteases, respectively. 
 
7.3.6 KD Determination with Thermolysin on SMM 
The ability to better enumerate the strength of binding interactions provides a useful 
window towards the convenient verification of potent inhibitors within huge chemical 
libraries.168 In an effort to demonstrate this capacity on a large-scale using SMM, we 
first applied a range of concentrations of thermolysin with all the inhibitors 
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Figure 7.7 Cladograms of metalloprotease based on SMM inhibitor fingerprints. The 
panel was clustered according to the complete dataset with the 1,400 inhibitors. 
Average linkage clustering was performed.  
 
with 8 concentration points over 16 SMM slides as shown in Figure 7.8A. The data 
was fitted to a saturation dynamics relation that assumes that when equilibrium is 
achieved, KD information may be extracted from resulting curves (Figure 7.8B). We 
were able to obtain binding profiles with good curve fits for 43 inhibitors that showed 
potencies of under 4.8 μM on the SMM (Table 11.8). This selection further satisfied 
our stringent criteria of accurate curve fits (r > 0.9) and significant binding signals 
(above 50% relative intensity) as observed on the arrays. To confirm the accuracy of 
the values obtained, we picked 3 representative inhibitors for independent validation 
using the surface plasmon resonance (SPR) platform (Figure 7.8C and Table 7.1). The 
comparison confirmed that the KD values obtained from the microarrays were very 
highly consistent to the same measures made using SPR (Table 7.1), highlighting the 
robustness and predictive power of SMM in KD determination.  
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 (B) (C) (A) 
Figure 7.8 Large-scale KD determination for thermolysin using SMM. (A) 8 different 
concentrations of protein were applied to the arrays (the magnified region illustrates 
the representative response from a section of the microarray). (B) The KD response 
curve from duplicated microarrays with L-A-R. (C) Fitted SPR results with L-A-R.   
 
7.3.7 KD Determination with Anthrax LF on SMM 
It has been an ongoing challenge to develop potent and selective inhibitors to treat 
intoxication of anthrax, in tandem with established antibiotic therapies available.16,19 
Various groups have reported low micromolar inhibitors uncovered using various 
chemical approaches.169 The most potent known inhibitor for Anthrax LF is a low 
nanomolar hydroxamate-based 14-mer peptide inhibitor that also strongly inhibits the 
serine protease, furin.170 With the aim to identify potent/ selective inhibitors to target 
Anthrax LF, we applied the enzyme in a concentration dependent manner on the 
arrays to rapidly obtain KD data of our library of inhibitors on the SMM. As earlier 
described, 16 printed hydroxamate microarray slides were used in duplicated 
experiments. Under the stringent fitting and intensity criteria set, we successfully 
obtained KD values for 85 inhibitors within the dataset (Table 11.8). This large scale 
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assessment attempts to quickly provide an overview of inhibitor potencies for a given 
combinatorial library. Though we were not able to obtain the KD for all the potentially 
strong binders (Filter 1), a significant proportion of the KD values were obtained, in a 
much quicker way than many other experimental approaches (eg. SPR/ Isothermal 
Calorimetry/ Fluorescence Polarization platforms). This highlights the potential of our 
approach for high-throughput screening. We went on to select several promising 
inhibitors across various grades of potency for further evaluation. IC50 measurements 
were performed for a panel of 9 inhibitors in solution phase microtitre plate based 
experiments (Table 7.2 and Figure 11.10). The data obtained confirmed that the 
microarray-based classification was indeed closely correlated with the inhibitor 
dataset. Of significant interest, one of the inhibitors identified, lF-F-L, was also found 
to be selective for Anthrax LF across the panel of enzyme screened in the Top 100 
analysis. This inhibitor provided a potent KD of 0.81 μM on the microarray and an 
IC50 of 2.0 μM. Several other inhibitors were identified, including F-W-L and I-Y-L 
that were confirmed to exhibit strong binding potencies with Anthrax LF (Table 7.2).  
7.3.8 Docked Position of Selected Inhibitor 
The identified inhibitor, lF-F-L was also employed for docking analysis with 
Anthrax LF. As would be expected, the optimized docking configuration of the 
inhibitor/enzyme complexes revealed the inhibitor adopted an extended conformation, 
comfortably fitting along the substrate binding groove in the enzyme active site 
(Figure 7.9). The hydroxamate group from the inhibitor was observed to chelate to the  
bound zinc atom while the P1’ side chain fitted deep into the S1’ pocket. It was further 
observed that the P2’ and P3’ positions of the inhibitor contribute to overall inhibition    
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Table 7.1 SPR was used to confirm the KD values obtained against thermolysin on the 
SMM for 3 selected inhibitors. A very good consistency was seen with the values 
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Table 7.2 K  and IC  results of selected inhibitors against Anthrax LF. 9 inhibitors 
identified from the library were subjected to IC  analysis for more detailed 
evaluation. The molecules are grouped as follows, according to the IC  results: high 










lF-F-L 0.81 2.0  
F-W-L 0.71 2.2  
I-W-L 0.74 5.5  
F-W-S 0.86 7.9  
I-A-A 2.6 14.0  
L-P-A 8.4 16.3  
L-A-C 2.4 29.6  
D-K-Q 5.6 >25  
L-P-E 4.5 >25  
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potency through the formation of hydrogen bonds and Van der Waals interactions 
with the protein. 




      
Figure 7.9 Docking configurations of lF-F-L with Anthrax LF. (A)The zinc ion in the 
active site is shown as a green sphere in the ribbon diagram. The image is expanded to 




The daunting task of screening huge chemical libraries has been ameliorated 
with the emergence of SMM. There have however been limited examples exploiting 
this platform in a global manner for the elucidation of physiologically relevant 
interactions. We herein introduce a method that enables practitioners to rapidly home 
in on biologically relevant hits using SMM. High-throughput screens performed using 
a focused library of peptide based hydroxamate inhibitors revealed reproducible, 
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unique and informative signatures for each enzyme tested. The platform also 
facilitated the discovery of inhibitors with low micromolar potencies against 
thermolysin (a thermostable enzyme) and anthrax lethal factor from Bacillus 
anthracis (a potential bioterror agent). Establishing functional differences through 
selective protein fingerprints using SMM will not only enhance the understanding of 
proteins in biological systems, but further accelerate the discovery of efficacious 
therapeutic leads.  
Overall the reciprocal dual-labeling strategy consumed minimal enzyme 
quantities and provided characteristic binding fingerprints for each enzyme tested. 
With the ability to independently manipulate proteins across each dye channel, 
potential false positives that contribute signals from the inactive channel can be 
readily removed from the analysis. By reciprocating the channels labeled across 
duplicate slides, enabling any dye bias, inherent systematic errors or endogenous 
fluorescence to be effectively removed from the analysis. This provides a 
conveniently implementable system for the elucidation of both reproducible and 
activity dependent results from SMM studies.  
Through our analysis, we uncovered several interesting results. Each 
metalloproteases provided unique inhibitor fingerprints, with those for Anthrax LF 
being the most distinct. For nearly all the metalloproteases tested, there were several 
uniquely potent inhibitors uncovered (Figure 7.5). Consistent with previous findings, 
we found that hydrophobic and aromatic side chains contribute greatly to inhibitor 
potency for all the enzymes tested. It was however not anticipated that our P’ inhibitor 
design could profile Carboxypeptidase A (being the only exopeptidase in the panel) 
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and produce a distinct fingerprint. The binding configurations of Carboxypeptidase 
could be further studied using co-crystallization with some of the most potent ligands 
uncovered, to understand the basis of these unexpected interactions. Overall, The 
most potent side chains included L, lF and F with aromatic side chains like W, F and 
Y in the P2’ and P3’ positions across all four metalloproteases (Figure 7.5B). It was 
further demonstrated that by analyzing profiles of varied protein concentrations 
applied to the microarray, we were able obtain measurements of dissociation 
constants that were consistent with those independently performed on alternative 
platforms, like SPR. We followed through with the analysis of several of the potent 
inhibitors against Anthrax LF and discovered that the potencies were replicated with 
IC50 screens performed on microplate. These revealed inhibitors such as lF-F-L and 
F-W-L that had low micromolar potencies against Anthrax LF. Furthermore, it was 
uncovered that lF-F-L was amongst one of the Top 100 inhibitors and was further 
selective to only Anthrax LF within the panel of enzymes screened. This makes it a 
promising candidate for further investigation and development.  
7.5 Conclusion 
In conclusion, the reciprocal dual-labelling strategy consumed minimal 
enzyme quantities and provided characteristic binding fingerprints for each enzyme 
tested. With the ability to independently manipulate proteins across each dye channel, 
potential false positives that contribute signals from the inactive channel can be 
readily removed from the analysis. Reciprocating the channels labelled across 
duplicate slides enabled any dye bias, inherent systematic errors or endogenous 
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fluorescence to be effectively removed from the analysis. This provides a 
conveniently implementable system for the elucidation of both reproducible and 
activity dependent results from SMM studies. In traditional SMM studies, it is 
frequently only the best binders that are deconvoluted, leaving the majority of the 
dataset uncharacterized. With every member of the array known a priori, we were on 
the other hand able to extract a wealth of information through comprehensively 
analyzing the complete dataset and performing protein fingerprinting on SMM. We 
further demonstrated the first large- scale determination of KD values for small 
molecule inhibitors using SMM, highlighting its potential significance towards 
accelerating discovery of potent molecules. Overall, our approach paves the way 
forward in microarray-driven research by fully capitalizing from the powerful 
capability and throughput offered on SMM, as well as providing useful information 
that can be used for comprehensive proteomic evaluation and future high-throughput 
screening applications. We predict that this technology can be expanded to screening 
complex biological specimens, like tumours or cell lysates to identify specific 
markers/inhibitors that may be selectively used to treat specific cancers. Further 
validation of some of the candidate inhibitors in vivo, could also provide for 









8.1 General Procedures 
8.1.1 Materials 
Active enzymes were acquired commercially, specifically thermolysin, 
Anthrax LF, MMPs -3, -7, -9 and -14 from Calbiochem (Merck, Germany). MMPs -2, 
-8 and -13 were obtained from Biomol International (Philadelphia, USA). Bacterial 
collagenase and all other enzymes were purchased from Sigma-Aldrich (Milwauki, 
USA) at the highest grade available and used directly without further purification. 
Fluorogenic substrates were purchased from Molecular Probes, Invitrogen (California, 
USA), List Biological Laboratories (USA), Calbiochem (Merck, Germany) and 
AnaSpec (California, USA). The EnzChek Protease Assay Kit comprising the bodipy 
casein substrate was obtained from Molecular Probes, Invitrogen (California, USA). 
A commercial broad-spectrum MMP inhibitor, GM6001, was obtained from 
Calbiochem, (Merck, Germany). Microplate experiments were performed in black 
flat-bottom polypropylene 384 well plates (Nunc, USA). Glass slides used for 
microarrays were 75mm X 25mm microscope glass slides from Sigma-Aldrich 




Microplates were scanned using a SpectraMaxTM Gemini XS fluorescence 
plate reader (Molecular Devices, USA). Where indicated, liquids were dispensed 
robotically using an automated liquid handler with 8-channel dispensing capability. 
(Precision XS, Biotek, Vermont, USA). Microarrays were printed using a contact 
arrayer (Virtek Chipwriter, Ontario, Canada). Microarrays were scanned on an 
ArrayWoRxTM microarray scanner (Applied Precision, USA) equipped with the 
relevant filters for coumarin (λex/em: 360/457 nm), bodipy/fluorescein (λex/em: 490/528 
nm), Cy3 (λex/em: 548/595 nm) and Cy5 (λex/em: 633/685 nm). Gels were scanned on a 
Typhoon fluorescence gel scanner (GE Healthcare, USA). Surface plasmon resonance 
measurements were performed on a Biacore 3000 instrument (Biacore AB, Uppsala, 
Sweden). ESI mass spectra were acquired in both the positive and negative mode 
using a Finnigan/Mat TSQ7000 spectrometer. Analytical RP-HPLC separations were 
performed on Phenomex C18 column (150 x 3.0 mm), using a Shimadzu Prominence 
HPLC system equipped with a Shimadzu SPD-20A detector. Eluents A (0.1 % 
TFA/acetonitrile) and B (0.1 % TFA/water) were used as the mobile phases.  
8.2 Synthesis of the 1,400 member Hydroxamate Peptide 
Library∗
Preparation of the hydroxamate inhibitors using solid phase synthesis was 
carried out as previously described.164a All chemicals were purchased at the highest 
available grade from commercial vendors and used without further purifications, 
                                                 
∗ The compounds used in this thesis were synthesized by my collaborators (Wang Jun, Li Junqi and Hu Mingyu) 
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unless otherwise noted. All reactions were carried out under an N2 atmosphere with 
HPLC grade solvents, unless otherwise stated.  
Briefly, the construction of the 1,400-member library was performed on rink 
amide resin by standard Fmoc solid phase peptide synthesis in microreactors (encoded 
with radio-frequency tags) using the IRORI™ split-and-pool directed sorting 
technology.171-172 The synthesis involved the use of minimal reaction bottles in three 
rounds of synthesis and sorting. The final products were released from support by 
standard TFA cleavage and purified by precipitation.173-174 A biotin linker was 
incorporated for alternative future applications of the library. The average 
concentration of individual inhibitors was estimated using aminomethyl 
carboxycoumarin (λex/em= 355/460nm) conjugated as a 1% additive in the final 
coupling step, as previously described. The final products were dissolved in 
dimethylsulfoxide to equivalent concentrations, diluted appropriately and used 
directly for subsequent high-throughput biochemical screens. Randomly selected 
products were positively confirmed by LC-MS and shown to be sufficient pure.   
8.3 Microplate-Based Enzyme Profiling Procedures  
8.3.1 High-Throughput Inhibitor Screening on Microplates 
8.3.1.1 MMPs with inhibitor libraries 
 Each enzyme was assayed using a suitable fluorogenic peptide substrate 
under optimized conditions. The assays were performed in black 384 well plates, 
using 50 μl total reaction volumes. Automated assembly of the reaction components 
was performed through an 8-channel robotic dispensing system. Upon enzyme 
 132
addition in the final step to initiate the reaction, the plates were incubated at 37 oC for 
intervals between 1-2 h, before being queried for endpoint fluorescence. In total, three 
different substrates were employed. First, TNO211 (DABCYL-GABA-Pro-Gln-Gly-|-
Leu-Glu (EDANS)-Ala-Lys-NH2; λex/em = 340/485 nm) was prepared to final 
screening concentrations of 3 μM for MMP-3 (60 fmol), 6.8 μM for MMP-9 (25 fmol) 
and 3.4 μM for MMP-14 (200 fmol). The samples were buffered in 100 mM Tris, pH 
7.5, supplemented with 300 mM NaCl, 10 mM CaCl2, 2 μM ZnCl2 and 0.02% Brij.175 
Secondly, MCA-Pro-Leu-Gly-|-Leu-Dpa-Ala-Arg-NH2 (λex/em= 325/393 nm) was 
applied at 3.2 μM and 1.6 μM for screening of MMP-2 (50 fmol) and MMP-7 (600 
fmol) respectively.176 The final substrate, MCA-Pro-Cha-Gly-|-Nva-His-Ala-
Dap(Dnp)-NH2 (λex/em= 325/393 nm) was optimized for MMP-13 (10 fmol) and 
MMP-8 (50 fmol) at reaction concentrations of 3.4 μM and 4 μM respectively.177 The 
latter 4 enzymes were buffered with 100 mM Tris pH 7.5 supplemented with 100 mM 
NaCl, 10 mM CaCl2 and 0.05% Brij-35. The optimized amount of enzyme utilized for 
each assay is italicized in parenthesis next to each named enzyme. The -|- position 
within the substrate sequence indicates the cleavage site. Each MMP was assayed 
against the entire 1,400-member library (normalized to a final reaction concentration 
of approximately 660 nM) in staggered runs.  
MMP-7 was also screened with the 96-member “click” inhibitor library. An 
optimized screening concentration of approximately 33 μM was used across all the 
inhibitors together with 1.6 μM substrate and 10 ng of MMP-7 in 50 μl assays 
buffered as earlier described.  
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8.3.1.2 Thermolysin with 400-member P1’ Leu hydroxamate inhibitors 
Thermolysin was screened against the 400-member sub-library presenting 
leucine in the P1’ position. Assays were performed under suitable conditions in black 
384-well plates and the reaction components were assembled robotically. Microplate 
experiments were carried out using the bodipy casein substrate. The cleavage of the 
substrate (prepared to a final reaction concentration of 4.4 μg/ml) (Molecular Probes, 
Invitrogen, USA) was monitored over 1 h in the presence of thermolysin and each of 
the inhibitor (final concentration: 660 nM). Each reaction was performed in a 50 μl 
volume, buffered in PBS (pH 7.4). Calcium was found not to be required in the buffer 
for observing high enzyme activity. Upon enzyme addition to 1.8 μM in the final step 
to initiate the reaction, the plates were incubated at 37 oC for 30 min, before being 
queried for endpoint fluorescence (λex/em= 490/528 nm) in staggered runs.  
8.3.1.3 Thermolysin and collagenase with the 96-member “click” inhibitor library 
Microplate experiments were performed in black 384-well plates with the 
bodipy casein substrate. Reactions were performed in duplicate in 50 μl volumes 
containing 5 μg/ml of the fluorogenic substrate, 33 μM of each inhibitor and 5 μg of 
enzyme suitably buffered in PBS (pH 7.4).  
8.3.2 IC50 Measurements 
8.3.2.1 MMPs 
Concentration-dependent measurements were performed to confirm the 
potency of representative inhibitors. Inhibitors exhibiting a range of potencies for 
each MMP were selected from the microplate screens and evaluated using IC50 
measurements. Briefly, dose-dependent reactions were performed by varying the 
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concentrations of the inhibitor, under the same enzyme-concentration. A two-fold 
dilution series from approximately 2 μM to 15 nM (final reaction concentration) was 
prepared for each inhibitor in black 384-well plates. Substrates and enzymes were 
applied according to the conditions earlier optimized. The plates were allowed to 
incubate for 1-2 h at 37 oC before being interrogated for end-point fluorescence.  
8.3.2.2 Thermolysin and collagenase 
The IC50 values were obtained using dose-dependent reactions by varying the 
concentrations of the inhibitor, under the same enzyme-concentration. Briefly, a two-
fold dilution series was prepared for each inhibitor to be tested in black flat-bottom 
polypropylene 384-well plates (Nunc, USA). 400 ng of enzyme 
(thermolysin/collagenase) was added to each of these dilutions and the reaction was 
initiated by introducing 0.5 μg of Bodipy FL casein to each well, bringing the final 
volume to 50 μl. The plate was allowed to incubate at room temperature for 1 hour 
before being interrogated for end-point fluorescence at λex/em = 485/530 nm.  
8.3.2.3 Anthrax LF 
A two-fold dilution series from approximately 25 μM to 390 nM (final 
reaction concentration) was prepared for each inhibitor in black 384-well plates. 
Substrates and enzymes for Anthrax LF were applied according to the following 
conditions - 0.2 pmol of the enzyme was combined with 2 nM MAPKKide substrate 
(List Biological Laboratories, USA) and inhibitor before being read at λex/em = 
490/520 nm, with a cutoff at 515 nM. The 50 μl reaction was buffered in 20 mM 
Hepes (pH 7.4) supplemented with 0.1 mg/ml BSA and 0.01% Tween 20. The plates 
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were allowed to incubate for 1 h at 37 oC before being interrogated for end-point 
fluorescence.  
8.3.3 Ki Measurements 
8.3.3.1 MMP-7  
A detailed evaluation was performed for the two strongest inhibitors identified 
from the “click” inhibitor library against MMP-7 (ie. F5 and G6).  These compounds 
were resynthesized and purified by HPLC. Dose-dependent reactions were performed 
by varying both the concentrations of the substrate and inhibitor, whilst maintaining a 
consistent enzyme concentration. Briefly, a two-fold dilution series from 
approximately 50 μM to 780 nM (final concentration) was prepared for each inhibitor 
to be tested in black flat-bottom polypropylene 384-well plates (Nunc, USA).  A final 
concentration of 2.7 μΜ, 1.8 μM and 460 nM of the coumarin substrate was added to 
each of these dilutions and the reaction was initiated by introducing 26 ng of MMP-7 
into a 50 μl reaction volume of MMP buffer. The plate was scanned immediately 
under the kinetic mode at λex/em = 325/393 nm at a 30s intervals for a period of 5 min.  
8.3.3.2 Thermolysin 
The Ki values were obtained using dose-dependent reactions by varying both 
the concentrations of the substrate and inhibitor, whilst maintaining the same enzyme 
concentration. Briefly, a two-fold dilution series from approximately 80 nM to 5 nM 
(final concentration) was prepared for each inhibitor to be tested in black flat-bottom 
polypropylene 384-well plates (Nunc, USA). 400 ng of Thermolysin was added to 
each of these dilutions and the reaction was initiated by introducing 1 μg, 0.5 μg and 
0.3 μg of bodipy casein substrate, bringing the final volume to 30 μl. The plate was 
 136
scanned immediately under the kinetic mode at λex/em = 485/530 nm at a 40 s intervals 
for a period of 8 minutes.  
8.4 Microarray-Based Enzyme Profiling Procedures 
8.4.1 Screening Enzymes Using Nanodroplet Microarrays  
8.4.1.1 Slide preparation 
Separate methods were used to immobilize each fluorogenic substrate: briefly, 
(1) poly-L-lysine slides were reacted with a 250 μM solution of ACC phosphate 
buffered in PBS (pH 7.4). The slides were rinsed with water to remove unassociated 
probe and stored at 4 oC in the dark until ready for use; (2) 3 μl of an original working 
bodipy casein substate stock solution was diluted into 25 μl PBS (pH 7.4) and applied 
to a N-hydroxysuccinimide derivatized slide, using the coverslip method as 
previously described.178 After a two-hour incubation, the slide was quenched with 
PBS containing a 0.5 M glycine solution. The resulting casein-coated slide was stored 
as earlier described. Both types of slides were stable for up to a month without an 
appreciable loss in activity, but were typically used within a week of preparation.  
8.4.1.2 Protein application 
A set of 39 proteins were prepared fresh from solid stocks, desalted by running 
through NAP-5 columns (Amersham Biosciences, UK), and titrated using the 
Bradford protein assay to within 0.3-3 mg/ml in PBS (pH 7.4). Enzymes were kept on 
ice until printing using SMP8B pins (TeleChem International Inc, USA) at a pitch of 
350 μm. The pins were rinsed between samples using two cycles of wash (for 10 s) 
and sonication (for 10 s) in reservoirs containing 70% ethanol followed by drying 
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under reduced pressure (for 10 s). Slides were incubated in a humid chamber with 
saturation above ~ 85% to minimize evaporation of the droplets followed by scanning 
and analysis.  
8.4.2 Inhibitor Screening Using Nanodroplet Microarrays  
Bodipy casein slides were prepared as earlier described. The enzymes were 
prepared to a 0.5 mg/ml concentration and mixed with approximately 2 μM of 
inhibitor. Enzymes were kept on ice until spotting. SMM spotting was done in 
duplicate with a spot spacing of 750 μm using SMP15B spotting pins (TeleChem 
International Inc, USA) (The pins produced ~9.4 nl spots with a diameter of 550 μm). 
The pins were rinsed between samples using two cycles of wash (for 10 s) and 
sonication (for 10 s) in reservoirs containing 70% ethanol followed by drying under 
reduced pressure (for 10 s). After spotting, slides were incubated in a dark, humid 
chamber for 2 hours with saturation above ~ 85% to minimize evaporation of the 
droplets followed by scanning and analysis.  
8.4.3 Labelling Metalloproteases on Protein Microarrays 
 
Selected proteins were spotted on hydrogel slides (Perkin Elmer, USA).  
Samples were spotted in 0.1M NaHCO3 (pH 9) in triplicate using SMP15B Pins 
(TeleChem International Inc, USA) with a spacing of 750μm between spots. The pins 
were rinsed between samples using two cycles of wash (for 10 s) and sonication (for 
10 s) in reservoirs containing 70% ethanol followed by drying under reduced pressure 
(for 10 s) The slides were incubated overnight at 4oC before blocking with 1% BSA in 
phosphate buffered saline (PBS) (pH 7.4) for 1hr. The slides were then treated with 
10μM of the Leu probe in 100ul PBS containing 1% BSA (pH 7.4) under coverslip 
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for 30min in a dark humid chamber at room temperature. Following irradiation under 
short wave UV for 20min and rinsing with PBS for 10min, the slides were scanned 
and analyzed.  
8.4.4 Inhibitor Fingerprinting of Metalloproteases on SMM 
8.4.4.1 Surface preparation 
Slides were cleaned in piranha solution (sulfuric acid/hydrogen peroxide, 7:3). 
An amine handle was incorporated onto the slides by silanization using a solution of 
3% (aminopropyl)triethoxysilane in 2% water and 95% ethanol. After a 1-2 h 
incubation, the slides were washed with ethanol and cured at 150ºC for at least 2 h. 
The resulting amine slides were incubated in a solution of 180 mM succinic anhydride 
in DMF for 30 min before being transferred to a boiling water bath for 2 min. The 
slides were rinsed with ethanol and dried under a stream of nitrogen. The carboxylic 
acid derivatized slide surface was activated with a solution of 100 mM of HBTU (O-
Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate), 200 mM 
DIEA, and 100 mM N-hydroxysuccinimide in DMF, thus generating the NHS-
derivatized slides. These surfaces were reacted with a solution of 1 mg/mL avidin in 
10 mM NaHCO3 (pH 9) for 40 minutes, washed with water, air dried. The unreacted 
NHS groups were quenched with a solution of 2 mM aspartic acid in a 0.5 M 
NaHCO3 buffer, pH 9. These slides were washed with water, dried and stored at 4ºC, 
ready for printing.  
8.4.4.2 Microarray printing 
Hydroxamate inhibitors stock solutions were prepared to ~2.5 mM in 50% 
DMSO with 50% PBS, and were distributed in 384-well plates. Slides were spotted 
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with 8 Stealth SMP8B Microspotting pins (Telechem, U.S.A.). Spots generated were 
of approximately 350 μm diameter and were printed with a spot-spot spacing of 450 
μm. The pins were rinsed in between samples using two cycles of wash (for 10 s) and 
sonication (for 10 s) in reservoirs containing 70% ethanol followed by drying under 
reduced pressure (for 10 s). The slides were allowed to stand for 1 h on the printer 
platform and stored at 4ºC until use. Before incubation with the labelled protein, the 
slides were rinsed with PBS (pH 7.4) for 20 min and blocked with PBS containing 1% 
BSA for 1 h. 
8.4.4.3 Protein application 
Protein samples were minimally labeled with Cy3 and Cy5 N-
hydroxysuccinimide esters (Amersham, G.E. Healthcare, USA) for 30 min on ice. The 
unreacted esters were quenched with a 10-fold molar excess of hydroxylamine or 
using 5 mM Tris, (pH 8.0) for a further 15 min. Excess dye was further removed by 
size exclusion on a Sephadex G-25 column (Amersham, G.E. Healthcare, USA). The 
labeled proteins were confirmed to retain their native enzymatic activity by positive 
cleavage of their respective fluorogenic substrates. The designated inactive channel 
protein was first heat treated at 95 OC for 10 min and immediately cooled on ice. 
Enzymatic activity was confirmed to be lost by this procedure using activity assays 
with respective fluorogenic substrates. The heat inactivated enzyme was then mixed 
with protein from the active channel and reconstituted in a final buffer volume of 100 
μl PBS (pH 7.4) containing 1% bovine serum albumin (BSA). A total of 
approximately 8 μg of protein (4 μg in each channel) was applied under coverslip to 
the arrays in this manner, and reciprocal experiments (with the designated dye 
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channels inverted) were performed in parallel. The samples were incubated with the 
arrays under coverslip in a humidified chamber for 2 - 4 h at room temperature, before 
repeated rinses with water, typically 2 times 2 min washes with gentle shaking. 
Excessive washing beyond 10 minutes was found to reduce correlations with 
microplate screening results. Slides were scanned and analyzed. Optimization of 
procedures was first carried out using thermolysin as a model, before general adoption 
with the other enzymes.        
8.5 Gel-Based Enzyme Profiling Procedures 
8.5.1 General Labelling Procedure 
Fingerprints against various metalloproteases were readily obtained using gel-
based experiments. Briefly, each probe was added at a final concentration of 500 nM 
to various enzymes in 20 μl reaction volumes buffered with 50 mM Tris.HCl (pH 8). 
Following a short thirty-minute incubation at room temperature in the dark, the 
samples were irradiated under low wavelength UV irradiation for a further 20 min. 
The reaction was quenched with the addition of SDS loading dye and subsequent 
boiling at 95oC for 10 min. Samples were resolved on a 10% denaturing SDS-PAGE 
gel and fluorescence was detected on a Typhoon fluorescence gel scanner (GE 
Healthcare, USA).  
8.5.2 Labelling in the Presence of Complex Cellular Lysates 
 
E. coli cell lysates were derived by growing XL1 Blue Gold cells to OD600 0.5 
in Luria Bertani (LB) Broth. The cells were pelleted and resuspended in PBS 
(containing 0.1% Tween) before being lysed by sonication. The protein extract was 
 141
separated from cellular debris through subsequent centrifugation for 40 min at 
20,000g and was found to produce only faint bands when screened with some of the 
probe library members. Thermolysin was spiked to 100 μg/ml in a concentration 
gradient of protein extract. The Leu probe was then added to a final concentration of 1 
μM and the mixture was incubated for 30 min and irradiated with UV as previously 
described.  
8.6 In Silico Molecular Modeling Procedures 
Docking was performed on a SGI IRIX 6.5 workstation using the SYBYL 
suite (version 7.2) installed with the FlexX docking software.157 Protein coordinates 
were obtained from the Protein Data Bank; specifically inhibitor complexed crystal 
structures with the following accessions were employed - MMP-2: 1QIB, MMP-7: 
1MMQ179 and Anthrax LF: 1YQY. Structures of representative inhibitors were drawn 
using the “Sketch Molecule” option and hydrogens were added. The biotin linker of 
selected inhibitors was excluded to simplify the docking simulations. The structures 
were minimized using 100 iterations at 0.05 kcal/mol Å to relieve any torsional strain 
and formal charges were assigned. The original protein structures were modified 
through the removal of water molecules. The docking sphere was set at 10-15 Å, 
centered at the zinc residue in the enzyme active site. Applying these criteria, the 
docking was performed for 30 iterations, with the most optimized configurations 
displayed. Proteins were displayed as either MOLCAD Connolly surfaces or ribbon 
diagrams.  
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8.7 KD Determination Using SPR 
Surface plasmon resonance measurements were performed on a Biacore 3000 
instrument. CM-5 chips were functionalized with avidin using standard procedures. 
The relevant test peptides were immobilized to approximately 400 response units 
(RUs). An adjacent chip flow cell was left unimmobilized for use as a reference for 
subtraction. Eight different concentrations of enzyme were applied in duplicate, in a 
3-fold dilution series ranging from 5 μM to 2.3 nM. A buffer comprising 10 mM 
HEPES (pH 7.4), 150 mM NaCl and 0.01% Tween 20 was used under a flow rate of 
30 μl/min. The chip surface was regenerated between samples with injections of 0.1 
M glycine (pH 2). The resulting data was analyzed using the BiaEvaluation software 
(Biacore AB, Uppsala, Sweden) under the 1:1 (Langmuir) binding model. Proper 
maintenance was performed to ensure that the instrument was kept in good running 
condition. The integrated flow cell and fluidic system was regularly washed, sanitized 
and desorbed using standard cleansing reagents, as recommended.  
8.8 Data Processing and Analysis 
8.8.1 Microplate Data 
8.8.1.1 High-throughput inhibitor screening  
Plate readings were exported from the scanner SoftmaxPro software into 
Microsoft Excel. Raw results were normalized by subtracting readings from the initial 
uncleaved substrate and inhibitor backgrounds. Data points from each plate were 
benchmarked against positive controls (these were essentially uninhibited samples, 
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with enzymes assayed without inhibitor, replicated at 5 wells per plate). The relative 
potencies of each inhibitor were calculated from the normalized data through the 
following relationship: 
Inhibition potency of x = ( 1- Measured intensity, xUninhibited intensity ) x 100% 
The combined dataset was also subjected to cluster analysis to correlate 
specificity information from the library into hierarchical contributions, providing 
unique inhibition-dependent profiles of MMPs. Averaged linkage clustering was 
performed using the Systat v11.0 software (San Jose, CA, USA). For comparison, 
active site domains comprising ~170 amino acid residues of human MMPs were 
retrieved from MEROPS180 and clustered using ClustalW181. The dataset was 
presented in both 3-D cube plots was performed using the Graphis software 
(Kylebank, UK) and coloured heatmaps using treeview 
(http://rana.lbl.gov/EisenSoftware.htm) software. Venn diagrams were generated 
using the Venn Diagram Generator 
(http://www.pangloss.com/seidel/Protocols/venn.cgi).  
8.8.1.2 IC50 analysis 
 
The IC50 was calculated by curve fitting against the concentration-dependent 
fluorescent plots using the Graphpad Prism software v.4.03 (GraphPad, San Diego, 
USA). The curves were fitted to a sigmoidal-dose response equation to solve the IC50 
value:  
                                       
             Y    = Minimum +  Maximum – Minimum     




X is the inhibitor concentration, 
Y is the percentage response is the activity relative to the enzyme control (no 
inhibitor), 
The Minimum and Maximum are the tops and bottoms of the sigmoidal curves 
(typically 0% and 100% respectively). 
8.8.1.3 Ki determination 
Kinetic data obtained were analyzed using the Dixon plot (1/initial velocity 
plotted against inhibitor concentration); affording three different linear graphs 
(corresponding to each of the substrate concentrations used) that converged on the 
horizontal axis (as is expected of classical non-competitive inhibitors) to give direct 
readouts of the Ki values. 
8.8.2 Microarray Data 
8.8.2.1 Nanodroplet microarray  
Microarray data was extracted using the ArrayWoRx software into Microsoft 
Excel. Mean spot intensities were background subtracted and averaged. Inhibition 
potency was calculated using normalization against equivalent concentrations of 
enzymes spotted without inhibitor.  
Inhibition potency of x = ( 1- Measured intensity, xUninhibited intensity ) x 100%  
 
The results were visualized using TreeView and cluster analysis was 
performed using average-linkage clustering with Gene Cluster.182   
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8.8.2.2 High-throughput protein fingerprinting on SMM 
Microarray data was extracted using the ArrayWoRx software into Microsoft 
Excel. Values from duplicate points were background subtracted and averaged. Raw 
signals arising from the inactive channel were thereafter deducted from the active 
channel to give the normalized activity dependent results for each experiment. 
Independent data from the reciprocal experiments was then combined by averaging. 
Points that were inconsistent across both channels were removed (>1 standard 
deviation fold variation between the two experiments). The combined dataset was 
scaled from 0% – 100% by fitting a maximum value within each enzyme dataset to 
100% (mean + 1 standard deviation point). The dataset was presented in both 3-D 
cube plots, using the Graphis software (Kylebank, UK), and as coloured heatmaps, 
using the Treeview software (http://rana.lbl.gov/EisenSoftware.htm). Position specific 
scoring matrix analysis was performed using software developed by Stephen Shaw 
(sshaw@nih.gov) and obtained and used with permission.183 The dataset was also 
subjected to cluster analysis to correlate specificity information from the library into 
hierarchical contributions, providing insights of inhibitor dependent similarities across 
the enzyme set. Averaged linkage clustering was performed using the Systat v11.0 
software (San Jose, CA, USA). For comparison, the active site domains were 
retrieved from MEROPS184 and aligned using ClustalW.181 Venn diagrams were 
generated using the Venn Diagram Generator 
(http://www.pangloss.com/seidel/Protocols/venn.cgi). 
8.8.2.3. Quantitative KD analysis on SMM 
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Using dose dependent protein application on the arrays we were able to 
extract KD values against all of the positively binding small molecules 
simultaneously. A threshold was set to restrict analysis to only positive binders. A 
protein concentration series diluted across a two-fold concentration range (from 4.8 
μM to 150 nM for Thermolysin and from 2.4 μM to 75 nM for Anthrax LF) applied 
on the microarrays in duplicate. The Cy3 channel was selected as the designate the 
active channel for this experiment. The microarray data was extracted using the 
ArrayWoRx software and fitted using the following relationship, under the 
assumption that equilibrium is achieved during the incubation period: 
 
Observed f luorescence of x =
[Maximum fluorescence, x] x [Protein concentration]
KD + Maximum fluorescence, x  
 
Saturation dynamics observed when plotting Observed fluorescence against 
the applied Protein concentration were then fitted to the above equation using the 
Graphpad Prism software v.4.03 (GraphPad, San Diego, USA) revealing the binding 
dissociation constant, KD, of the various positively identified small molecules. Only 
fits that correlated accurately with the experimental results (r > 0.9) were accepted.   
8.8.3 Gel-Based Labelling Data 
Observed fluorescence bands corresponding to the labelled proteins and were 
quantitated using the ImageQuant software (GE Healthcare, USA). Cluster analysis 
was performed using Gene Cluster using average linkage clustering and visualized 












  Herein I have desribed a series of technologies that span microplate and 
microarray platforms and facilitate high-throughput enzyme profiling. These tools 
have been tested successfully using metalloproteases. The results indicate that such 
systematic experimentation would provide comprehensive insight into the behaviours 
of virtually any cluster of enzymes. The functional profiles obtained from inhibitor 
screening contributes towards the understanding of the enzymes and proteins and the 
development of predictive models for their functional perturbation. The probes 
developed may also be applied for the annotation and discovery of novel enzymes. 
The technological solutions offer frontier capabilities towards the rapid evaluation and 
characterization of proteins. Overall the high-throughput strategies demonstrate the 
global evaluation of proteins at various levels and dimensions, contributing insight 
and discovery towards in the burgeoning proteomics arena.  
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11.1 Supplemental Tables 
Table 11.1 Names and Classification of MMPs (adapted from refs. 10, 180 and 185). 
MMPs have been classified to 5 families according to sequence homology, substrate 
preference and cellular localizations. In total, 7 MMPs were screened representing all 
5 families.  
 
Group name Enzyme Common Name E.C. Number Tested herein 
MMP-1 Collagenase 1 3.4.24.7  
MMP-8 Collagenase 2 3.4.24.34 9 
MMP-13 Collagenase 3 Not yet denoted 9 COLLAGENASE 
MMP-18 Collagenase 4 (Xenopus) Not yet denoted  
MMP-2 Gelatinase A 3.4.24.24 9 GELATINASE MMP-9 Gelatinase B 3.4.24.25 9 
MMP-3 Stromelysin 1 3.4.24.17 9 
MMP-10 Stromelysin 2 3.4.24.22  STROMELYSIN 
MMP-11 Stromelysin 3 Not yet denoted  
MMP-14 MT1-MMP 3.4.24.80 9 
MMP-15 MT2-MMP Not yet denoted  
MMP-16 MT3-MMP Not yet denoted  MEMBRANE-TYPE 
MMP-17 MT4-MMP Not yet denoted  
OTHERS MMP-7 Matrilysin 3.4.2.33 9 
 MMP-12 Macrophage Elastase 3.4.24.65  
 MMP-19 (No trivial name) Not yet denoted  
 MMP-20 Enamelysin Not yet denoted  
NON-MAMMALIAN XMMP  (Xenopus) Not yet denoted  
 CMMP  (Gallus domesticus) Not yet denoted  
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Table 11.2 Library design for 1400-member hydroxamate peptides. The 20 natural 
amino acids were used in the P2’ and P3’ position for in the Leu library, whilst a 
representative set of 10 amino acids (Nonpolar: Ala, Leu, Phe, Trp, Charged polar: 
Glu, Lys, His and Uncharged polar:  Gln, Ser, Tyr) was utilized for permuting all 
other sublibraries.  
 
P1’ P2’ P3’ Sub-Library Size 
L 20 natural amino acids 
20 natural 
amino acids 400 members 
I, V, F, lF, K, 




amino acids 1000 members 
Total: 11 P1’ warheads       Total: 1400 compounds 
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Table 11.3A Selective inhibitors uncovered from the top 100 inhibitor lists. Inhibitors 
listed (in order of name) reflect the specific inhibitors that were exclusive to 
respective MMPs from within the top 100 inhibitor list. (These inhibitors each 
demonstrated inhibition potencies from the high-throughput screen of >75% against 
respective MMPs). Identities are defined as P1’ - P2’ - P3’. Inhibitors in bold were 
further characterized using IC50 measurements against the MMP panel.   
 
No. MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-13 MMP-14 
1 Cp-Q-Q Ch-E-E Ch-L-Y L-A-A L-K-G Cp-Q-L Ch-E-K 
2 F-E-W Ch-H-K Ch-Y-F L-A-H F-W-S Cp-S-L Cp-E-K 
3 F-F-F Ch-H-S Ch-Y-L L-A-S K-Y-S Cp-S-S F-H-K 
4 F-F-K Ch-K-H Cp-A-F L-A-W lF-F-H L-R-C F-Q-K 
5 F-F-L Ch-K-Y Cp-A-L L-H-T lF-F-W L-N-V I-H-K 
6 F-F-W Ch-W-S Cp-A-W L-I-H lF-W-F L-C-S I-Y-F 
7 F-K-A Cp-A-S Cp-A-Y L-I-Y lF-W-H L-L-I K-Y-W 
8 F-L-W Cp-W-K Cp-F-E L-K-H lF-Y-W L-L-T L-D-P 
9 F-W-W D-A-Q Cp-F-F L-K-T Sf-F-S L-L-Y lF-A-K 
10 F-Y-S D-E-E Cp-F-K L-N-A Sf-L-H L-K-E lF-E-H 
11 I-S-Q D-E-S Cp-F-L L-Q-S Sf-W-H L-F-D lF-K-L 
12 K-E-A D-F-E Cp-H-F L-Q-T  L-F-C lF-L-L 
13 K-E-E D-L-E Cp-H-H L-R-D  L-F-Q L-F-P 
14 L-A-I D-Q-E Cp-H-K L-S-A  L-F-E lS-Y-F 
15 L-A-V F-F-E Cp-H-L L-T-A  L-S-S V-Q-H 
16 L-A-Y F-H-S Cp-H-W L-T-G  L-S-V V-Q-S 
17 L-C-R lF-F-Q Cp-H-Y L-W-M  L-T-P V-S-W 
18 L-E-D lF-H-Q Cp-K-Q L-W-N  lF-H-S  
19 L-E-P lF-K-E Cp-K-W L-W-Q  lF-K-W  
20 lF-A-Q lF-S-Q Cp-K-Y L-Y-D  lF-W-W  
21 lF -E-Q lS-F-A Cp-L-H   lF-Y-L  
22 lF -E-S lS-F-E Cp-L-L   F-E-A  
23 lF -H-F lS-F-S Cp-L-Y   F-W-H  
24 lF -H-L lS-H-A Cp-Q-A   Sf-Q-H  
25 lF -H-Y lS-S-S Cp-Q-F     
26 lF -K-K Sf-H-Q Cp-Q-S     
27 lF -K-Y Sf-L-A Cp-Q-W     
28 lF -L-Y Sf-L-Q Cp-Q-Y     
29 lF -S-E Sf-Q-Q L-I-E     
30 L-G-T Sf-Y-Q L-I-F     
31 L-H-F  L-I-I     
32 L-L-K  L-K-I     
33 L-M-M  L-K-W     
34 L-M-R  L-Q-L     
35 L-M-T  L-Q-M     
36 L-N-E  L-Q-W     
37 L-P-R  L-Q-Y     
38 L-Q-P  L-V-E     
39 L-R-Q  L-V-F     
40 L-S-D  L-V-I     
41 L-T-F  L-V-K     
42 L-V-D  L-V-S     
43 L-W-C  L-V-T     
44 L-W-I  L-V-V     
45 L-W-L  L-V-W     
46 L-Y-K  L-V-Y     
47 L-Y-L       
48 L-Y-M       
49 L-Y-Q       




Table S11.3B Broad-range inhibitors uncovered from the top 100 inhibitor lists. The 
top 100 inhibitors from each MMP were analyzed to compare inhibitor selectivity. 
Listed are the specific inhibitors that appeared in the top 100 list of 5 MMPs. 
Identities are defined as P1’ - P2’ - P3’.  Inhibitors in bold were further characterized 
using IC50 measurements against the MMP panel.   
 
No. Inhibitor MMPs targeted 
1 Cp-W-A -2, -7, -3, -9, -13 
2 lF-F-A -2, -3, -9, -13, -14 
3 L-F-G -2, -8, -9, -13, -14 
4 L-F-Y -2, -8, -9, -13, -14 
5 lF-Y-A -2, -3, -9, -13, -14 
6 L-I-A -3, -7, -8, -9, -14 
7 L-I-S -7, -8, -9, -13, -14 
8 L-L-A -2, -8, -9, -13, -14 
9 L-W-H -2, -8, -9, -13, -14 
10 L-W-T -2, -8, -9, -13, -14 
11 L-W-W -2, -8, -9, -13, -14 
12 L-Y-N -2, -8, -9, -13, -14 




Table 11.4 Motif selectivity comparisons. The inhibitor selectivities exhibited from 
this study were tabulated with known substrate preferences for each MMP (from both 
peptide-based10, 119 and protein based substrate motifs126). This highlights the general 
similarities observed, with subtle differences when comparing substrate profiles and 
inhibitor profiles. Single letter amino acid codes are used to denote all the preferred 
residues listed at positions from P3 to P3’. The 3 most potent residues from the 
averaged profiles are shown from the present study and displayed in bold if also 
observed to be preferred in substrate sequences.   
 
  Position  
Enzyme Common Name P3 P2 P1 P1
’ P2’ P3’ Ref. 
P,V, I V, A S, G, A, 
E 
L, M, I, 
Y, F 
R, Y, 
K, M, I, 
V 
S, A, G (119) 
P, S, V Q, F, A, 
S, R 
G, N, W I, L, Y A, L, R, 
N 
G, F, T (10) MMP-2 Gelatinase A 
N. A. N.A. N.A. lF, L, F F, W, Y A, S, Q Chapter 
2 
P,V,I F, Y, L, 
M, A, 
S, E M, I, L, 
Y, F 
M, K, I, 
R 
M, A (119) 
P, S, V Q, F, A, 
R, S 
G, N, W I, L, Y A, L, R, 
N 
G, F, T (10) MMP-3 Collagenase 1 




A, S, E Chapter 
2 
P, V, I L, M, 
Y, 
S, E, N, 
A 
L, I, M V, T, I, 




P, A, V L, I, Q, 
E 
E, P, G, 
A, Y 
L, M, I, 
Y 
R, S, A, 
Y, V, K 
A, I, G, 
L, F 
(10) MMP-7 Matrilysin 








P Q G L, I A, L, W G (19) 
MMP-8 Collagenase 2 N.A. N.A. N.A. Cp, L, 
lF 
W, Y, F A, S, Q Chapter 
2 
P, V L, Y S L, M, I, 
Y, F 
R, T, Y, 
V, I 
S, A, G (119) 
P,S, A P, G, F, 
I, L, R 
G, S, H V, L, I, 
A 




(10) MMP-9 Gelatinase B 
N.A. N.A. N.A. L, Sf, 
Cp
W, Y, F A, S, W Chapter 
2 
P L, A, R, 
K 
G M, L R, H, K G, A, D (126) 
P, L, V Q, G, A G, R, E I, F, M A, Q, R G, T (10) MMP-13 Collagenase 3 N.A. N.A. N.A. lF, Cp, 
L 
W, Y, F A, S, L Chapter 
2 
P, V X S, A L, I, M, 
Y, F 
R, K, Y M, A (119) 
S, P, T Q, V, C N, D, Q F, L, T F, V G, V, T (10) MMP-14 MT1-MMP 




Table 11.5 The classification of the panel of 4 metalloproteases used in the study. The 
enzymes in our panel were divided across two broad clans MA(E) and MC clans of 
metalloproteases, which differentiates the endopeptidases from the exopeptidase, as 








Clan MA(E) >> 
Family M4 
HEXXH 
Anthrax LF Bacillus anthracis Clan MA(E) >> 
Family M34  
HEXXH 
Collagenase colA Clostridium 
histolyticum 









Table 11.6 Motif selectivity comparisons. The inhibitor selectivity exhibited from this 
study were tabulated with known substrate preferences for each metalloprotease (from 
both peptide-based and protein based substrate motifs). This highlights the general 
similarities observ , with subtle diff ces when comparing substrate profiles and 
inhibitor profiles. Single letter amino acid codes are used to denote all the preferred 
residues. The top 4 most potent residues are displayed from each study. The top 4 
from the averaged profiles are shown for the present study and displayed in bold if 








































































Table 11.7A Selective inhibitors uncovered from the top 100 inhibitor lists. Inhibitors 
listed (in order of name) reflect the specific inhibitors that were exclusive to 
respective metalloproteases from within the top 100 inhibitor list. Identities are 
defined as P1’ - P2’ - P3’. Inhibitors in bold were further characterized with quantitative 
measurements. 





1 L-A-R D-F-W Cp-F-A Ch-F-S lF-E-Y 
2 F-L-W Cp-H-F Cp-F-L Ch-K-L lF-F-L 
3 L-A-C C -Q-Q Cp-F-Y Ch-K-W lF-
4 L-A-K  Cp-W-A Ch-L-W lF-L-S 
5 L-A-P F-Y-A Cp-W-Q Ch-Q-L L-F-M 
6 L-A-Q F-Y-S Cp-W-S Ch-S-S lF-Q
7 L-A-S I-E-E Cp-Y-L Ch-W-K lF-Q
8 L-A-V I-L-L F-F-F Ch-Y-A lF-Q
9 L-H-C I-Q-L F-F-Q Ch-Y-K lF-S
10 L-H-R F-F-Y Ch-Y-S L-H-L 
11 L-I-K F-H-W Cp-K-Y L-I-Y 
12 L-I-P I-W-Y F-Y-L Cp-L-Q L-P-F 
13 L-L-F K-K-F F-Y-Q Cp-L-S lS-A
14 L-L-P K-W-S I-F-A Cp-Y-S lS-L
15 L-M-K K-Y-L I-F-Q Cp-Y-Y lS-S-E 
16 L-M-Y L-C-L I-K-L D-K-A L-S-W 
17 L-P-C L-C-T I-L-W D-K-Q lS-Y
18 L-Q-K lF-E-W K-W-F D-Q-Q lS-Y
19 L-Q-P L-F-F K-W-W D-W-E L-V-W 
20 L-Q-W L-F-G lF-A-W D-W-L L-W-K 
21 L-R-A lF-L-Y lF-F-A D-W-Q L-Y-A 
22 L-R-Q lF-F-Y F-E-L L-Y-V 
23 L-V-A lF-H-L F-H-Q Sf-F
24 L-V-K L-H-W lF-H-W F-L-K Sf-K-E 
25 L-V-R L-M-G L-F-L F-Q-F Sf-L-Q 
26 L-W-F lS-A-A lF-Q-H I-A-Y Sf-Q
27 L-W-I lS-F-W lF-Q-W I-F-L Sf-W
28 L-W-M L-Y-G lF-W-E I-L-F V-F-F 
29  Sf-S-K lF-W-H I-Q-Q V-F-K 
30  V-S-L lF-W-Q I-S-Q V-H-F 
31  V-Y-L lF-Y-F I-S-S V-Q-F 
32   lF-Y-Q I-W-K V-S-Q 
33   lF-Y-Y I-Y-Q V-W-A 
34   L-G-L K-L-E V-W-K 
35  L-W-G K-S-A V-Y-Y 
36    K-S-S  
37    K-S-W  
38    K-W-Q  




























Table 11.7B Broad-range inhibitors uncovered from the top 100 inhibitor lists. The 
top 100 inhibitors from each metalloprotease were analyzed to compare inhibitor 
selectivity. Listed are the specific inhibitors that appeared in the top 100 list of all 
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11.2 Supplemental Figures 
  
MMP-2                     MMP-3 
  












Figure 11.1 Inhibition potencies with the complete 1,400 inhibitor library against 7 
MMPs. Each inhibitor is represented by spheres plotted according to the P1’, P2’ and 
P3’ identities in the cube plot. Relative potency is indicated by both the color spectrum 
(blue - least potent, red - most potent) as well as by size of the sphere (small - least 






















   
MMP-2 C -W-A p
     
MMP-2 L-I-G 
 
ocking configurations of selected inhibitors with MMPs. The zinc 
esidue in the enzyme active site is chelated with the hydroxamic group of the 
inhibitor. The peptide chain of the inhibitor is shown to straddle the substrate binding 
groove of the enzyme.  The following PDB accessions were used to obtain protein 
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Figure 11.3 IC50 determination for selected inhibitors with MMP panel. A panel of 









 Figure 11.4 Graphs for determining IC50 values of selected inhibitors against 
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Figure 11.6 Graphs for determining IC50 values o
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                     I. Thermolysin   II.  Collagenase 
         
 
 
                    III.  Carboxypeptidase         IV. Anthrax LF    
 
 
Figure 11.7 The data combined from both reciprocal experiments were presented in a 
3D cube plot for enzymes in the panel. Each sphere co-ordinate in the plot 
corresponds to the P1’, P2’ and P3’ identities of the inhibitors allowing binding 
intensities of all 1,400 cognate members to be visualized simultaneously. Relative 
potency is indicated by both the color spectrum (blue - least potent, red - most potent) 
as well as by size of the sphere (small - least potent, big - most potent). Only data that 
was highly discordant between the reciprocal experiments were excluded. 
Nevertheless a significant proportion of the data, 70% of the data in the case of 
collagenase, 75% for Anthrax LF, 90% for carboxypeptidase and 95% for thermolysin 
were consistently reproduced across the reciprocal channels. Statistical correlation 
between the duplicated experiments was strong (r > 0.8) with thermolysin providing 




Figure 11.8 Averaged inhibition contributions permuted across P1’, P2’ and P3’ 
positions. Each bar represents averaged inhibition across inhibitors in the library 
presenting the relevant residue. The error bar denotes the standard deviation across 
each group of inhibitors. Though information was lost by averaging because of 
consolidation of individual inhibitor sequences into general categories, this analysis 
provided for a broader analysis of the data and a snapshot view of the results, 
depicting each residues overall bearing to potency.          
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Figure 11.9 Protein sequence alignment of the selected metalloproteases.  
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Figure 11.10 IC50 and KD curves for selected inhibitors with Anthrax LF. A panel of 
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